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Abstract 
Prostate cancer (PCa) is the second most common form of cancer in men around 
the world. In many parts of Africa, data on prostate cancer is sparse. This is 
attributed to poor access to testing and diagnostics. The International Agency for 
Research on Cancer (GLOBOCAN) estimated that 28,000 deaths occurred as a 
result of PCa in Africa in 2008, 4500 of which were in South Africa. This figure 
(28,000) is predicated a rise to 57,000 over the next two decades. Currently, the 
most commonly used diagnostic tests for PCa are the DRE and PSA tests. The 
former is highly invasive and both have low specificity and poor sensitivity. 
Therefore, the need for a less invasive early detection method with the ability to 
overcome the lack of specificity and sensitivity is required. Biomarkers have 
recently been identified as a viable option for early detection of disease. 
Examples of biological indicators for disease are miRNAs. miRNAs are small 
non-coding RNA molecules which play a key role in controlling gene expression 
and certain biological processes. Studies have shown that aberrantly expressed 
miRNAs are a hallmark of several diseases like cancer. miRNA expression has 
been shown to be associated with tumour development, progression and response 
to therapy, suggesting their possible use as diagnostic, prognostic and predictive 
biomarkers.  
The study aimed to investigate the potential of miRNAs implicated in prostate 
cancer as putative biomarkers for the disease and evaluating these miRNAs in a 
panel of prostate as well as several other cancer cell lines using qRT-PCR. An in 
silico approach was used to identify 13 putative miRNAs implicated in prostate 
cancer of which 8 were further analysed in a parallel study and 5 in this study. 
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Two publicly available target prediction software were used for target gene 
prediction of the 5 identified miRNAs. The target genes were subjected to 
functional analysis using web-based software, DAVID. Functions which were 
clustered with an enrichment score of 1.3 and greater were considered significant. 
Targets with gene ontologies linked to “transcription regulation”, “regulation of 
“apopotosis”, “extracellular region” and “metal ion binding” were considered for 
further analyses. Protein gene interaction analysis was performed to determine the 
pathways the target genes are involved in using STRING. Expression profile 
analysis of the genes in various tissues was also carried out using in silico 
methods through the TiGER and GeneHub-GEPIS databases. 
 
Analysis using DAVID resulted in 9 gene targets for the 5 miRNAs. It was found 
that miR3 seemed the most promising miRNA for biomarker validation based on 
the in silico analyses. Its target gene MNT was found to be abundantly expressed 
in prostate tissue from the TiGER results. The GeneHub-GEPIS results also 
indicated that the gene’s expression is up-regulated during prostate cancer. 
The expression levels of the miRNAs analysed using qRT-PCR indicated that 
miR3 is significantly over-expressed in prostate cancer cells when compared to 
the other cancer cell lines used in this study, corroborating the results observed 
from the in silico analyses. Another miRNA with interesting results was miR5. It 
was predicted to target two genes, YWHAZ and TNFSF13B. In TiGER, both 
were found to be expressed in prostate tissue. The genes were also found to be up 
regulated during prostate cancer in GeneHub-GEPIS. The expression level of 
miR5 in LNCaP was 15.32; it was significantly up-regulated in the cell line using 
qRT-PCR. However, miR5 was also present in HEPG2-7.06, MCF7-0.79, HT29-
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1.61 and H157-3.59. Thus, it was concluded it can be used as a biomarker in 
combination with other miRNAs. The miRNA miR2 was found to target the actin 
filament protein encoding gene AFAP1. The gene was predicted to be up-
regulated with a DEU of 33.25 in GeneHuB-GEPIS. The qRT-PCR analysis 
showed that the expression ratio in LNcaP was 8.79. However, miR2 expression 
was up-regulated in MCF7-0.85 and HT29-1.09 as well. The expression level of 
miR1 in BHP1 was found to be 4.85. It can be considered as an indicator for 
benign prostate hyperplasia.  
  
Future work would include investigating the expression of miR3 in a larger panel 
of cancer cells as well as in patient samples. In addition, analysis of the UTR 
sequences of the miRNAs targets experimentally to prove that the target genes 
identified using in silico methods, are indeed regulated by these miRNAs. 
Furthermore, performing gene “knock-out” studies on the genes that code for the 
miRNAs to study their roles in prostate cancer development.  
November, 2015 
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Chapter 1 
Literature Review 
 
1.1 Cancer 
 
One of the greatest health concerns worldwide currently is cancer. It has become 
the most devastating disease among the chronic diseases.  It has continued to rise 
in incidence and is associated with a high morbidity and mortality rate, in 2012; 
there were 8.2 million cancer related deaths (CDC, 2014).  According to the 
National Cancer Institute statistics, there are over 13 million new cases of cancer 
per annum worldwide, and the number of new cases is expected to rise by 70 % 
by 2050 with deaths projected to rise to over 12 million worldwide by 2040 
(WHO, 2015). Additionally, the Cancer Association of South Africa reports that 
one in six males and one in seven females have some type of cancer with prostate 
cancer being most prevalent in the former and breast cancer in the latter.  
Cancer arises in almost all human tissues and it is believed that the basic 
processes that transform a normal cell into a cancer cell are essentially the same 
in all cancers arising in the human body. These basic properties of survival, 
proliferation and dissemination are called the hallmarks of cancer (Hanahan and 
Weinberg, 2000). Although these hallmarks are thought to be common for all 
types of cancer, they are acquired through diverse distinct mechanisms during 
different times of the multistep tumourigenesis process in different forms of 
cancer. There are six hallmarks of cancer(figure 1) originally proposed by 
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Hanahan and Weinberg, these are: i) sustaining proliferative signalling, ii) 
evading growth suppressors, iii) activating invasion and metastasis, iv) enabling 
replicative immortality, v) angiogenesis and vi) resisting cell death (Hanahan and 
Weinberg, 2011).  
 
 
Figure 1: The six hallmarks of cancer acquired by normal cells as they evolve to 
a neoplastic state (Adapted from Hanahan and Weinberg, 2011). 
 
1.1.1 Hallmarks of cancer 
 
The hallmarks of cancer have been defined as acquired functional capabilities that 
allow cancer cells to survive, proliferate, and disseminate (Hanahan and 
Weinberg 2000; Hanahan and Weinberg 2011). These functions are acquired in 
different tumour types via distinct mechanisms and at various times during the 
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course of multistep tumourigenesis (Hanahan and Weinberg 2000; Colotta et al., 
2009). Recently, an increasing body of research has suggested that two additional 
hallmarks of cancer are involved in the pathogenesis of some and perhaps all 
cancers. One involves the capability to modify, or reprogram, cellular metabolism 
in order to most effectively support neoplastic proliferation (Hanahan and 
Weinberg 2011; Colotta et al., 2009; Luo et al., 2009). The second allows cancer 
cells to evade immunological destruction, in particular by T and B lymphocytes, 
macrophages, and natural killer cells (Hanahan and Weinberg 2011; Colotta et 
al., 2009; Negrini et al., 2010). Because neither capability is yet generalized and 
fully validated, they are referred to as emerging hallmarks (Hanahan and 
Weinberg, 2011).  
Additionally, two consequential characteristics of neoplasia facilitate acquisition 
of both core and emerging hallmarks (figure 1.2). Genomic instability and thus 
mutability present cancer cells with genetic alterations that drive tumour 
progression (Colotta et al., 2009; Luo et al., 2009). Inflammation by innate 
immune cells designed to fight infections and heal wounds can instead result in 
their inadvertent support of multiple hallmark capabilities, thereby manifesting 
the now widely appreciated tumour-promoting consequences of inflammatory 
responses (Hanahan and Weinberg 2011; Colotta et al., 2009; Luo et al., 2009; 
Negrini et al., 2010). 
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Figure 1.2: Emerging Hallmarks of cancer and Enabling Characteristics. 
(Adapted from Hanahan and Weinberg, 2011). 
 
 
1.2 Prostate cancer (PCa) 
 
Prostate cancer is one of the most common cancers among men worldwide. 
According to the International Agency for Research on Cancer (GLOBOCAN) in 
2012, prostate cancer was among the most commonly diagnosed cancers in 
males, coming second after lung cancer. Prostate cancer makes up 8 % of all 
cancers diagnosed in the world for both sexes (figure 1.3).  
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The incidence of PCa varies significantly between ethnic groups and geographic 
regions with men of African descent living outside of Africa having some of the 
highest incidence rates, 234.6 per 100,000 (Chang et al., 2011; Rebbeck et al., 
2013). In the USA, men of African descent are more frequently diagnosed with 
PCa at an earlier age of onset, have higher prostate specific antigen levels, higher 
tumour volume as well as more aggressive tumour stages (Zeeger et al., 2004; 
Lange et al., 2008).  
 
 
Figure 1.3: The most commonly diagnosed cancers worldwide (for males and 
females) in 2012, with prostate cancer accounting for 8 %. (Adapted from 
GLOBOCAN, 2012). 
 
 
Mortality rate among people of African descent is also higher than that of 
Caucasian Americans with the latter having 25.6 deaths per 100,000 men and the 
former having 2.4 times that rate at 62.3 per 100,000 men (Chang et al., 2011). In 
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contrast, prostate cancer incidence in Asian countries is low (Curado et al., 2007) 
and reasons for this are not clear. However, studies do indicate that these patterns 
may be linked to differences in access to care, inherited susceptibility, referral 
patterns, differences in the biology of the disease, treatment options, differences 
in testing, reporting and diagnosis of the disease. (Parkin et al., 2003; Rebbeck et 
al., 2013). 
 
In many parts of Africa, data on prostate cancer is sparse. This could be because 
of poor access to testing and diagnostics. The International Agency for Research 
on Cancer (GLOBOCAN) estimated that 28,000 deaths occurred in Africa in 
2008 and predicated a rise to 57,000 over the next two decades. However, a study 
by Chu et al.,2011 questioned the validity of these figures, stating that they could 
be an underestimation of PCa cases in Africa. In their study on PCa among 
different racial groups in the Western Cape, Heyns et al., 2011, suggestes the 
underestimates could be as a result of less awareness and education about the 
disease among patients and physicians as well as the fear and taboo of possible 
digital rectal examinations.  
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1.2.1 Anatomy and normal functions of the prostate 
The prostate is a compound exocrine gland that is part of the male reproductive 
system (Figure 1.4) (Theodorescu, 2001). The normal adult prostate is about the 
size of a walnut and increases in size with age. It is situated at the base of the 
bladder and surrounds the urethra. The rectum sits posterior to the prostate, 
allowing for palpation of the prostate during rectal examination (Basch et al., 
2012). The secretions of the prostate are high in sugars and proteins. The prostatic 
secretions are thought to be important in aiding fertilization by increasing the 
motility of sperm and perhaps promoting the viability of sperm after ejaculation. 
The gland produces approximately 20 % of the fluid produced during ejaculation 
(Gupta et al., 2013). The glandular tissue of the prostate is dependent on 
androgens for normal growth and development; androgens are hormones that 
promote the development of male sexual characteristics, the most common being 
testosterone (Theodorescu, 2001).   
 
 
 
Figure 1.4: Anatomy of the prostate gland. (Adapted from Theodorescu, 2001). 
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In terms of structure, the prostate is clinically divided into zones (figure 1.4). 
These are the peripheral zone (PZ), which comprises of the posterior part of the 
gland surrounding the distal urethra and it has been reported that 80 % of cancers 
arise in the PZ (Taylor et al., 2011).  The central zone (CZ) surrounds the 
ejaculatory ducts and approximately 5 % of cancers are reported to arise here 
(Descotes et al., 2007). Figure 1.3 also shows that the transition zone (TZ) 
surrounds the proximal urethra and continues to enlarge throughout life and is the 
part of the gland where benign prostatic hyperplasia (BPH) occurs in later life. 
About 15 % of cancers originate from the transition zone (Taylor et al., 2011).   
 
Figure 1.5: Zonal anatomy of the prostate. The human prostate is composed of zones 
of exocrine glandular tissue with the ducts emptying into the prostatic urethra. (Adapted 
from Cramer, 2007). 
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1.2.2 Prostate cancer pathology 
The prostate has two main epithelial cell types; the basal cells and the luminal 
cells (Theodorescu et al., 2001). The latter lines the lumen of the prostate and is 
responsible for the production of a protein known as the prostate specific antigen 
(PSA). There has been no record of any other cell in the male body producing this 
protein and thus it is used as a biomarker for prostate cells. The basal cells 
surround the luminal cells and act as a barrier between the luminal cells and the 
stroma (Taylor and Albertsen, 2011). During the development of prostate cancer, 
the normal prostate structure is altered, the rate of cell division surpasses cell 
death and this leads to uncontrolled tumour growth. These changes result in a 
breakdown of the basal cell barrier between the prostatic duct and the surrounding 
stroma. These breakdowns lead to an invasion of luminal cells into the 
surrounding stroma, which can eventually lead to migration of these cells into the 
rest of the body using the nervous or circulatory systems (Huang et al., 2013). 
Arriving at their final destination, the tumour cells can lodge and grow secondary 
tumours which can result in a dramatic decline in the cure rates for the disease. 
The presence of these prostate cancer cells in another site, such as bone, does not 
change its classification to bone cancer-for instance. The new tumour is still 
considered to be prostate cancer (Taylor and Albertsen, 2011).  
1.2.3 Benign Prostatic Hyperplasia 
Benign Prostatic Hyperplasia (BPH) arises from the glandular epithelial cells that 
line the ducts of the prostate gland.  Although the pathogenesis of BPH is not 
well understood, it is generally agreed that it begins with stromal alterations, 
which then stimulate growth and variably alter the differentiation of associated 
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epithelial cells (Taylor and Albertsen, 2011).  It is interesting to note that most 
prostate cancers arise in prostates that already have BPH. However, BPH 
originates in the transitional zone while the peripheral zone is the most 
prevalent site for prostate cancer. BPH is easily distinguished from prostate 
cancer histologically, as BPH has a distinct basal cell layer and is characterised 
by an altered stromal-epithelial arrangement (Descotes et al., 2007). 
 
BPH is the most common non-malignant condition to affect men and is the most 
frequent benign condition found in the prostate, occurring in more than 70 % of 
men aged 70 years or older (Taylor et al., 2011). Although BPH is not the 
premalignant precursor of prostate cancer (Basch et al., 2012), this condition has 
significant similarities with prostate cancer. Both show increased prevalence with 
age (although BPH usually occurs 15-20 years earlier), they both require 
androgenic stimulation and may respond to androgen deprivation (Botswick and 
Brawer, 1987).  The current clinical marker for prostate cancer, PSA, is known to 
increase with age and is also associated with BPH (Gupta et al., 2013).  Thus, 
there may be considerable uncertainty when distinguishing between BPH and 
prostate cancer using the PSA test (Basch et al., 2012). 
 
1.2.4 Prostatic intraepithelial neoplasia: A precursor to prostate 
cancer 
The piling up of luminal cells in the prostate is called Prostatic Intraepithelial 
Neoplasia (PIN). PIN is thought to bea precursor to prostate cancer and is usually 
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segregated into low grade and highgrade, depending on how closely it resembles 
true prostatecancer (Taylor and Albertsen, 2011). Prostatic intraepithelial 
neoplasia retains a basal cell layer, distinguishing it from prostate cancer, which 
lacks a basal celllayer. In figure 1.6, the normal luminal cells are very similar to 
one another in size, shape, and the location of the nucleus toward the basal layer 
(Botswick and Brawer, 1987). In low-grade PIN the luminal cells become less 
uniform; the nuclei are no longer located solely at the basal layer, instead they 
become enlarged and contain large dark spots referred to as nucleoli. In high-
grade PIN these characteristics become more pronounced, the nuclei become very 
large and the nucleoli are very prominent. In early prostate cancer (carcinoma), 
there is an additional loss of the complete basal layer. 
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Figure 1.6: Cellular changes in Prostatic Intraepithelial Neoplasia (PIN). The progressive changes in the structure of the gland 
are seen going from left (normal) to right (microinvasive carcinoma). (Adapted from Boswick and Brawer, 1987).
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1.3 The Gleason grading system 
One of the defining attributes of prostate cancer that distinguishes it from PIN 
and the normal prostate glands is the loss of the basal layer of cells (Boswick and 
Brawer, 1987). However, loss of the basal layer is not the end of the process of 
changes in the prostate that lead to aggressive prostate cancer. Just as with PIN, in 
which there are low-grade and high-grade classifications of aggressiveness, there 
are specific changes that occur in the prostate that have been associated with 
more or less aggressive disease (Taylor and Albertsen, 2011). There are several 
systems that have been developed to classify these changes and correlate them 
with patient survival and response to therapy. The system that is used throughout 
the world is the Gleason grading system developed by Donald Gleason in the 
1960s (Oesterling and Moyad, 1997; American Joint Committee on Cancer, 
2010). It is a standardized system of grading histological changes in the prostate 
glandular structure that could be used to predict prostatic disease progression 
(Gleason, 1966). Figure 1.7 shows a figure that Gleason published in 1966 that is 
still used by pathologists to grade prostate cancer using the Gleason system. The 
figure represents the appearance of the prostate glandular morphology at low 
magnification using a microscope.  
 
In figure 1.7, looking at panel 1, each circle represents the lumen of a duct or 
gland. Gleason noticed that as the prostate cancer becomes more aggressive the 
glandular structure becomes less uniform and more disorganized. This 
organization is often referred to as the degree of differentiation. The more 
organized (grade 1), the more differentiated. The less organized the less 
 
 
 
 
14 
 
differentiation and the more aggressive the cancer (grade 5) (Gleason, 1966). 
From 1 to 5, each number represents an increasing Gleason grade. There are a 
variety of glandular types that can be classified as belonging to each specific 
grade. As the Gleason grade increases, the size and shape of the glands become 
less uniform. In very advanced cancer, Gleason grade 4 or 5, the glands become 
very tiny, or in some cases there is a loss of glandular structure completely 
(Oesterling and Moyad, 1997).  
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Figure 1.7: Gleason Grading System. As prostate cancer becomes more aggressive, the glands become less organized, 
withsmaller and more variable lumen sizes. Each panel from 1 to 5 represents an increasing Gleason grade. (Adapted from 
Foster and Bostwick, 1998). 
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1.3.1 Tumour staging 
Whilst grading refers to how aggressive a cancer can be, cancer staging is the 
process of determining whether the cancer has spread and how far. Staging also 
provides a better insight into the risk of the disease spreading further so that the 
correct treatment option can be selected. The TNM stage was developed by the 
American Joint Committee on Cancer (AJCC) (Wallace et al., 1975). It is used to 
evaluate the extent of the primary tumour (T), the affected regional lymph nodes 
(N) and if it has spread or metastasized (M) table 1.  
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Table 1: TNM staging of prostate cancer. 
 
Primary  
Tumour 
(T)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TX 
T0 
Ta 
T 
 
      
T2 
 
 
 
 
T3 
 
 
 
T4 
 
 
 
Cannot evaluate the primary 
tumour 
No evidence of primary 
tumour 
Non invasive papillary 
carcinoma 
Carcinoma in situ: flat tumour  
 
Tumour invades muscle 
T2a Tumour invades 
superficial muscle (inner half)  
T2b Tumour invades deep 
muscle (outer half) 
 
Tumour invades perivesical 
tissue   
T3a Microscopically 
T3b Macroscopically 
 
Tumour invades prostate 
T4a Tumour invades prostate 
T4b Tumour invades pelvic or 
abdominal wall 
 
 
Regional  
Lymph 
Nodes (N) 
 
 
 
 
 
 
NX 
 N0 
 N1 
 
 
 
Regional lymph nodes cannot 
be assessed 
No regional lymph node 
metastasis 
Metastasis in a single lymph 
node  
 
 
 
Distant  
Metastasis  
(M) 
 
 
 
 
 
 
MX 
M0 
M1 
 
 
 
 
Distant metastatic cannot be 
assessed 
No distant metastatic 
Distant metastatic   
 
 
M, metastasis; N, nodes; T, tumour. (Adapted from American Joint Committee on 
Cancer, 2013). 
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1.4 Diagnosis 
Diagnosis of prostate cancer includes testing for the presence of prostate-specific 
antigen (PSA) in blood testing, PSA velocity (how much a patient’s PSA levels 
increase from year to year), digital rectal examination (DRE), blood count and 
biochemical profiling, transrectal ultrasound (TRUS) and biopsy (Horwich et al., 
2010). Secondary diagnosis can occur during investigation for other diseases, 
such as bladder cancer, where biopsies may be undertaken.  
 
1.4.1 Prostate-specific antigen testing 
Currently, prostate cancer screening is done in part through the use of the prostate 
specific antigen (PSA) blood test often combined with a digital rectal exam 
(DRE). Not all low or high PSA levels are indicative of prostate cancer, as PSA 
levels are organ specific and not cancer specific (Descotes et al., 2007; Velonas et 
al., 2013; Qu et al., 2014). Despite routine application of PSA assays, PSA 
screening has been very controversial. As of October 2011, the United States 
Preventive Services Task Force (USPSTF) recommended against the use of PSA 
as a screening tool for prostate cancer in asymptomatic men. The controversy 
around use of PSA as a screening tool stems from the fact that PSA is organ-
specific and not disease-specific, thus making it prone to high false-positive 
diagnosis. In addition to prostate cancer, there are several reasons for elevated 
levels of PSA found in a man's blood. These include: benign prostate hyperplasia, 
prostatitis (Basch et al., 2012), recent ejaculation, digital rectal exam, and 
prostate biopsy. Biopsies show that over two-thirds of men with PSA levels 
greater than 4 ng/mL, do not have prostate cancer (Descortes et al., 2007). In the 
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meantime, there are men with PSA levels in the normal range (below 4ng/mL) 
who have prostate cancer (Heidenreich et al., 2011). According to the Mayo 
Clinic, 76 % of men with raised PSA levels do not test positive for it upon biopsy 
(Tollefson, 2012). Additionally, in 2004, Thompson et al conducted a study over 
a period of 7 years in 2,950 males who had never had PSA levels higher than 4.0 
ng/mL or an abnormal DRE. Prostate biopsies showed that there was a 15.2 % 
(n=449) prevalence of PCa in men with PSA levels no higher than 4.0 ng/mL. 
High-grade prostate cancer (defined as Gleason score ≥7) was also seen in 15.8 % 
(n = 71) of these men. 
 
In 2006, Dyche et al., investigated the prevalence and outcome of PSA testing for 
prostate cancer screening or diagnosis in men 45 years to 75 years of age over a 
period of 6 years. The study was conducted on 8797 males and a total of 82,672 
visits were made over the time period. The findings were that 5.7 % of these men 
underwent at least one PSA test. Of that 5.7 %, 3.4 % were under the age of 55. 
Overall, the prevalence of PSA testing was 14.9 % in the 45 to 54 years old age 
group and 11.8 % in the 55 to 64 years old age group and 10.3 % in the 65 to 75 
years old age group. The study concluded that PSA testing for prostate cancer 
screening and diagnosis appears to decrease with advancing age. The study was 
however, not conclusive on why this happens. It could be because of the 
problems associated with PSA discussed afore mentioned.  
 
Another important limitation of PSA as a biomarker is its inability to identify 
patients with aggressive and lethal forms of prostate cancer. Because many forms 
of prostate cancer are apathetic and do not progress to metastasis and death, it 
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would be important for new biomarkers to be able to distinguish those from 
aggressive prostate cancer (Heidenreich et al., 2011). Over the last 25 years, no 
new blood test, genetic test or medical x-ray have been able to replace PSA. So 
we are in a midst of a biomarker crisis as lack of specificity of PSA requires 
supplementation in order to improve patient management, and to differentiate 
cancer from benign diseases of the prostate. 
 
1.4.2 Digital rectal examination (DRE) 
Digital rectal examinations are performed by a clinician physically examining the 
prostate via the rectum for any bumps or enlargements. A normal prostate is 
about the size of a walnut and uniformly soft and pliable.  Areas of prostate 
cancer will often feel harder than the surrounding normal area. The hardened part 
is called the nodule (Heidenreich et al., 2011).  The prostate can also be larger 
than normal; however this is due to BPH rather than prostate cancer. About 18 % 
of patients with prostate cancer can be diagnosed by a DRE regardless of PSA 
levels (Carter et al., 2013). A DRE can indicate whether a prostate biopsy is 
recommended for a patient, especially in more aggressive cases (Horwich et al., 
2010). However, like PSA testing, DREs are not absolutely conclusive. DREs are 
dependent on the ability of a doctor to feel the differences between a normal 
prostate and a tumour. If the cancer is located away from the rectal surface or if it 
is not particularly hard, then it might be missed. Because of such problems, the 
American Urological Association (AUA) 2013 guidelines could not find evidence 
to support the continued use of DREs for first-line screening due to its lack of 
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sensitivity and the high possibility of missing early prostate cancer tumours, 
which may not be felt during the examination (Horwich et al., 2010).  
The National Health Institute (NIH) in the UK release statistics on digital rectal 
examinations for the year 2014. In the report, it is indicated in a test group of men 
aged between 50 and 70 years old only 47.6 % underwent a DRE (Federman et 
al., 2014). An additional 6.9 % were offered a DRE but declined. The study 
concluded that screening for prostate cancer remains controversial. Nevertheless, 
the DREs are still the standard test used for prostate cancer in conjunction with 
other diagnostic tests such as PSA. 
 
1.4.3 Transrectal ultrasound (TRUS) 
A Transrectal ultrasound is performed by inserting a small probe in the patient’s 
rectum; this probe emits sound waves into the patient’s prostate that echo back to 
the probe to create video images of the prostate (Basch et al., 2012). The TRUS 
can sometimes detect tumours that may not have been detected by a DRE, and it 
may also give clinicians a better idea of PSA density, which can help distinguish 
between BPH and prostate cancer (Descotes et al., 2007).  
 
1.4.4 Biopsy 
A biopsy can be ordered as a follow up on a PSA test, DREs and/or or imaging 
tests. However, there are many factors that should be considered before a biopsy. 
The patient’s medical history, age, ethnicity, heredity, other present diseases, as 
well as results from any other preceding tests are all factors to consider. A biopsy 
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is a procedure in which a sample of body tissue is removed and examined under a 
microscope (Basch et al., 2012).  A core needle biopsy is the main method used 
to diagnose prostate cancer. Using transrectal ultrasound to have an image of the 
prostate gland, a clinician then inserts a thin, hollow needle through the wall of 
the rectum into the prostate. When the needle is pulled out it removes a small 
cylinder of prostate tissue. This can be repeated from 8 to18 times (Horwich et 
al., 2010). While biopsies and an analysis of the tumour histology can allow 
clinicians to appropriately determine the patient’s disease and its severity, the 
biopsy procedure can also lead to adverse events, such as infection, bleeding, and 
urinary difficulties (Carter et al., 2013). There is also a risk of false diagnosis. 
This can happen if the needle misses the tumour (American Cancer Society, 
2012).  
Thus, an ideal screening test should be minimally invasive, accurate and 
conveniently available to the general population. It should also be able to provide 
an accurate and early diagnosis. The current diagnostic methods for prostate 
cancer as discussed above are lacking in sensitivity and specificity. They are 
uncomfortable and maybe potentially harmful not only physically but 
psychologically and lead to patient apathy towards them. Thus, a molecular 
marker that is inexpensive, sensitive enough to detect the disease before tumour 
formation and remains unaltered during disease progression is necessary.  
1.5 Biomarkers 
The discovery of cancer biomarkers has become an integral part of medicine. A 
reason why biomarkers have revolutionized the medical field is because they are 
 
 
 
 
23 
 
effective non-invasive indicator molecules. The National Cancer Institute (NCI) 
defines biomarkers as any biological molecule that is isolated from body fluids 
such as urine, blood or tissue that is a sign of a normal or abnormal process in the 
body or disease condition. They are objective indications of a medical state 
observed from outside the patient, which can be measured accurately and is 
reproducible (Strimbu and Tavel, 2010). 
Biomarkers can also be used to assess the effectiveness of particular therapies in 
improving the effects of a disease. By using easily obtained biomarkers to 
monitor a patient's reaction to a particular drug, it is possible to determine 
whether treatment is effective for that individual by measuring drug response 
rates or toxic effects associated with the drug (Kulasingam and Diamandis, 2008). 
During any biological process or disease progression, organs secrete biological 
markers that reflect the occurrence of physiological function (Good et al., 2007). 
Tumours and cancer cells release RNA, DNA and proteins such as growth factors 
and cytokines into circulation (De Bock et al., 2009). Thus these released 
molecules are able to pinpoint the organ they originated from to facilitate the 
detection of the problem or disease. As a consequence biological fluids such as 
urine, plasma, serum or cerebrospinal fluid are good sources for mining 
biological indicators to distinguish a disease state from the non-diseased state 
(Mayuex., 2004). 
Specific clinical biomarkers have the potential to revolutionize the diagnosis and 
treatment of a variety of medical conditions. The lack of current methods of 
detection of many diseases at an early stage is a major factor in the prevalence of 
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diseases. Thus, the objective of biomarker discovery is to identify specific 
molecular markers susceptible to improve early diagnosis, survey therapeutic 
outcomes and facilitate the development of novel drug candidates (de Bock et al., 
2010). The assumption that the pathology of concern will affect some 
physiological processes causing changes at the molecular or protein expression 
levels, is the fundamental approach to biomarker discovery (de Bock et al., 2010).  
 
 
1.5.1 Types of biomarkers 
Cancer biomarkers can be classified into five categories: risk assessment, 
screening/diagnostic, prognostic, predictive, and pharmacodynamic (figure 1.8). 
Risk assessment biomarkers use studies on chromosomal aberrations, micronuclei 
and other changes deemed to represent genomic damage to select for potential 
disease onset in high risk individuals (Vaini, 2001; Teixeira et al., 2105). 
Prognostic biomarkers predict the natural course of the cancer as well as   
distinguish the tumour's outcome. Biomarkers also help determine whom to treat, 
how aggressively to treat, and which candidates will likely respond to a given 
drug and the most effective dose. Predictive biomarkers evaluate the probable 
benefit of a particular treatment. Pharmacodynamic biomarkers assess the 
imminent treatment effects of a drug on a tumour and can possibly determine the 
proper dosage in the early stages of clinical development of a new anticancer 
drug (Sawyers, 2008). 
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Instead of analyzing the tumour cells themselves, the molecular composition of a 
tumour can be indirectly characterized by analyzing blood samples and searching 
for variations in serum proteins, thereby improving the precision of screening and 
curtailing the need for invasive diagnostic procedures. Some difficulties were 
encountered initially in an attempt to reproduce these cancer associated serum 
proteins. With advances in our ability to measure quantitatively, collect 
standardized samples, and resolve the problems of reduced sensitivity in 
detection, confidence in the results of this approach has risen (Sawyers, 2008). 
Measurements from biomarkers can be used to adjust empirical results of clinical 
trials by establishing a relationship between the effects of interventions on 
molecular/cellular pathways and clinical responses, thereby providing a way for 
scientists to comprehend mechanistically the differences in clinical response that 
may be affected by uncontrolled variables (Atkinson et al., 2001). 
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Figure 1.8: Types of biomarkers and their impact on cancer management. (Adapted from Chen et al., 2012).
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Studies have shown that aberrantly expressed miRNAs are a hallmark of several 
diseases like cancer (Croce et al., 2009). miRNA expression has been shown to 
be associated with tumour development, progression and response to therapy, 
suggesting their possible use as diagnostic, prognostic and predictive biomarkers 
(Iorio and Croce 2012). Because of these characteristics, miRNAs have been 
emerged as potential as diagnostic, prognostic, and treatment response 
biomarkers.  
 
1.6 MicroRNAs 
miRNAs are naturally occurring endogenous, single stranded RNA molecules. 
They are 18 -24 nucleotide bases long and are non-protein coding (Munker and 
Calin, 2013). miRNAs control gene expression by binding to target mRNAs with 
imperfect complementarity within the 3’-UTR, leading either to their repression 
of translation or degradation (Cannell et al., 2008). They were first discovered in 
Caenorhabditis elegans (C. elegans) by Ambros and colleagues in 1993. Since 
their discovery, they have become the subject of intensive research which has 
amassed a wealth of information on their biogenesis, function and significance in 
gene regulation. miRNAs play important roles in a wide range of biological 
processes including cell proliferation and differentiation, organ development, 
apoptosis, as well as regulation of several processes related to eukaryotic 
development (Ardekani and Naeini, 2010).  As a consequence, misregulation at 
any point of these processes owing to abnormal miRNA mutation or expression 
can result in cancer.  
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The understanding of the mechanisms of action of miRNAs is still in its infancy. 
However, to date, work in this area has suggested that miRNAs may regulate 
gene expression at either the transcriptional or the post-transcriptional level. This 
may be by either suppressing translation of protein coding genes, or cleaving 
target mRNAs to induce their degradation (Bartel, 2004). 
Currently, there are 2154 mature human miRNAs that have been reported 
(MiRbase, V21 www.mirbase.org ) and they have been predicted to regulate up to 
60% of the human protein coding genes. 
 
1.6.1 Biogenesis of MicroRNAs 
A larger number of miRNA genes are situated in intergenic regions or in 
antisense orientation to annotated genes (Lee and Ambros, 2001; Lagos-Quintana 
et al., 2001; Lau et al., 2001) this indicates that they are distinct transcription 
units. There are however, a small number of the human miRNA genes that are 
located in intronic regions and are transcribed as part of annotated genes (Yang et 
al., 2011).  
 
Biogenesis of miRNAs in humans is a two-step process which involves both 
nuclear and cytoplasmic cleavage events carried out by Drosha and Dicer (Denli 
et al., 2004; Lee et al., 2001). The miRNA genes are transcribed by RNA 
polymerase into primary polyadenylated miRNA transcripts called pri-miRNAs. 
Pri-miRNAs consist of one or more hairpin structures each with a stem loop and a 
terminal loop. They bear a 3’ polyadenylated tail and a 5’ over hang capped by a 
7-methylguanosine. pri-miRNAs can also produce more than one functional 
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miRNA (Melo and Melo, 2014). Pri-miRNAs are processed into precursor 
miRNA and subsequently into an miRNA duplex which then releases the mature 
miRNA (Bartel et al., 2004). 
 
The intergenic miRNA is transcribed by RNA polymerases II and III to produce 
primary miRNA, which as discussed earlier, is a stem looped structure with single 
stranded RNA overhangs at the 3’ end and the 5’ end (MacFarlane and Murphy, 
2010). Whilst still in the nucleus, a protein complex called the microprocessor 
comprised of RNase III endonuclease Drosha and the double-stranded RNA-
binding protein DiGeorge syndrome critical region gene 8 (DGCR8) (figure 1.9) 
cleaves the pri-miRNA into a 70 nucleotide hairpin structure called the pre-
miRNA (Du and Zamore, 2005). The DGCR8 protein recognizes the stem and the 
flanking single-stranded RNA and serves as a ruler for Drosha to cut the stem 
about 11 nucleotides away from the stem–ssRNA junction, releasing the pre-
miRNA (Melo and Melo, 2014). 
 
The miRNAs located within introns of protein coding genes are transcribed by 
RNA polymerase II (Rodriguez et al., 2004). Two possible miRNA pathways for 
the maturation of pri-miRNA have been proposed for intronic miRNAs (Figure 
1.9). These processes may occur simultaneously or independently. In one such 
pathway referred to by some researchers as the non-canonical pathway, some 
miRNAs known as mirtrons bypass the Drosha step. Instead, introns are excised 
out of the pri-miRNA by spliceosomal components. The product is a pre-miRNA 
that continues to the cytoplasm for maturation (Kim et al., 2007).  The alternative 
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pathway, called the canonical, is the same as that of the intergenic miRNAs, 
involving cleavage with Drosha (Melo and Melo, 2014). 
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Figure 1.9: Nuclear section of miRNA biogenesis. 
Intergenic miRNAs are transcribed by RNA polymerase III producing a pri-miRNA molecule, which is processed into a precursor 
miRNA (pre-miRNA) by the microprocessor complex comprised of DGCR8 and Drosha. Pre-miRNAs are exported to the 
cytoplasm by Exportin 5 and Ran-GTP which are nucleocytoplasmic transporters. Intronic miRNA are transcribed by RNA poly 
II. The miRNA sequence is excised from the pri-mRNA by spliceosomal components to liberate a mirtron which is exported to 
the cytoplasm. (Adapted from MacFarlane and Murphy, 2010). 
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The export of the pre-miRNA from the nucleus to the cytoplasm is facilitated by 
the nucleocytoplasmic transporter factor Exportin-5 which is a RanGTP-
dependent dsRNA binding protein (Bohnsack et al., 2004).  At this point, the pre-
miRNA is a stem looped structure about 60-70 nucleotides long.  In the 
cytoplasm, as seen in figure 1.10, an RNase III enzyme Dicer, in a complex with 
its binding partner the transactivator RNA-binding protein (TRBP), binds to the 
pre-miRNA on the second nucleotide at the 3’ overhang. Dicer then cleaves off 
the terminal base pairs and the loop of the pre-miRNA. This results in a double 
stranded RNA structure called the miRNA:miRNA* duplex with 3’ overhangs. 
This structure contains the mature miRNA strand (22 nucleotides in length) and 
its complementary strand denoted by an asterisk (Li et al., 2007).  The mature 
miRNA strand is then loaded onto miRISC, which is a miRNA associated RNA-
induced silencing complex. miRISC contains an Argonaute protein (Ago 2) 
which catalyzes the cleavage of mRNAs (figure 1.10). Thus it is also a protein 
responsible for translational repression (MacFarlane and Murphy 2010). The 
complementary strand is degraded.                         
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Figure 1.10. Cytoplasmic component of microRNA biogenesis. 
Pre-miRNA is cleaved by Dicer to generate an miRNA duplex. The miRNA duplex liberates the mature miRNA to assemble into 
a RISC loading complex comprised of Ago2, TRBP, PACT and Dicer. The mechanism of mature miRNA release is unclear. 
(Adapted from MacFarlane and Murphy, 2010). 
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The mechanism of the miRNA and RISC assembly is not well understood in 
humans. There are many hypotheses with regards to the unwinding of the duplex. 
There is evidence however, that the process is ATP-independent. Gregory et al., 
2005, hypothesised that Dicer cleaves the passenger strand and thus initiates the 
unwinding of the duplex, releasing the mature single strand that is captured by 
Ago2.  Another hypothesis by Maniataki et al., 2005, is that conformational 
changes in miRISC during assembly could also cause the duplex to unwind 
simultaneously. The mature miRNA incorporated into the RISC guides the 
complex to target mRNAs with complementary sequences to inhibit their 
translation via mRNA cleavage, mRNA destabilization or translational repression 
(Bartel, 2004). 
 
 
1.6.2 Regulation of miRNA biogenesis. 
As discussed earlier, miRNAs play important roles in a wide range of biological 
processes such as cell differentiation, organ development, and apoptosis. 
Therefore, stringent control of their levels is critical to maintaining normal 
cellular functions and any deregulation of miRNA expression is often associated 
with human diseases, such as cancer (Jiang et al., 2009). As such, it is highly 
important to have the biogenesis of miRNAs subject to regulation at various 
levels, from transcription, processing, sequence identity, and binding to target 
mRNAs.  
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Transcription is a major point of regulation in miRNA biogenesis. Many miRNA 
gene promoters have characteristics that are similar to protein-coding gene 
promoters. Therefore, the same mechanisms of gene expression control such as 
use of silencers, specificity factors and repressors can be employed (Ozsolak et 
al., 2008; Corcoran et al., 2009). miRNA genes can be transcribed by either RNA 
polymerase II or III. A wide range of regulatory options can be facilitated as each 
enzyme is regulated differently and recognizes specific promoters and terminators 
(Melo and Melo, 2014). 
Regulation can also occur during the Drosha processing pathway. Drosha and 
DGCR8 levels in the cell are tightly controlled and as such play an important role 
in the regulation of pri-miRNA processing (Davis et al., 2008). The protein 
DGCR8 has a stabilizing effect on Drosha by interacting with its middle domain, 
and Drosha can control the levels of DGCR8 by cleaving hairpins in mRNA 
coding for DGCR8 thus leading to its degradation (Triboulet et al., 2009). 
Therefore, a well controlled equilibrium needs to exist between the amounts of 
Drosha and DGCR8 to maintain the processing of pri-miRNAs. 
 
 
1.6.3 Function of miRNAs 
miRNAs play a vital role in regulating numerous metabolic and cellular 
pathways, notably those controlling cell proliferation, differentiation and survival 
(Bushati and Cohen, 2007). For these purposes, an miRNA is complementary to 
one or more mRNAs. In animals the complementary site is usually in the 3’-UTR 
(Cannell et al., 2008). Perfect or near perfect complementarity promotes cleavage 
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of the mRNA. However, nucleotides 2-7 of the miRNA have to be perfectly 
complementary (Lagos-Quintana et al., 2001). Binding of miRNA to the mRNA 
can inhibit protein translation or accelerate the process of deadenylation causing 
the mRNA to be degraded (Melo and Melo, 2014).  
 
Dysregulation of miRNA expression has been demonstrated in most tumours 
examined (Gong et al., 2005). However, the specific classification of miRNA as 
oncogenes or tumour suppressors can be difficult because of the intricate 
expression patterns of miRNAs. These expression patterns differ for specific 
tissues and differentiation states and this poses two difficulties in classification 
(Bartel et al., 2004; Jiang et al., 2009). Firstly, it is not always clear if altered 
miRNA patterns are the direct cause of the cancer or rather an indirect effect of 
changes in cellular phenotype. Secondly, a single miRNA can regulate multiple 
targets (MacFarlane and Murphy, 2013). This, coupled with tissue specific 
expression could, implicate a single miRNA as a tumour suppressor in one 
context and an oncogene in another. 
 
 
1.6.4 miRNA regulation in cancer 
Since the discovery of miRNAs in 1993, their regulation has been involved in a 
large variety of physiological processes. miRNAs were first reported to be 
dysregulated in cancer in 2002, when Calin and co-workers described a deletion 
at 13q14 in chronic lymphocytic leukaemia. The miR-15/miR-16 clusters are 
located on this locus and are not only down-regulated in these tumours but also 
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regulate B-cell lymphoma 2 expression. Early studies also suggested that there 
was a predominant down regulation of miRNAs (Lu et al., 2005) and DICER 
expression down regulation in cancer supporting this hypothesis (Karube et al., 
2005). However, further studies revealed both up and down regulation of miRNA 
in all solid tumours and leukaemias (Calin et al., 2002). However, some miRNAs 
seem to have a tissue-specific function and are only expressed in specific cancers; 
others are universally over or under-expressed in cancer. For example, miR-21 
has been shown to be up-regulated in almost all solid tumours, including prostate, 
breast, lung, pancreas, stomach, and colon tumours (Chan et al., 2005; Karube et 
al., 2005). 
 
 
1.6.5 miRNAs as tumour suppressors and oncogenes 
It is well documented that up-regulation or down-regulation of miRNAs occurs in 
various human cancers (Zhang et al., 2007, Vaz et al., 2013). Over-expressed 
miRNAs may function as both oncogenes (through down-regulation of tumour-
suppressor genes) and/ or regulators of cellular processes such as cell 
differentiation or apoptosis (He et al., 2005, 2007). 
 
Let-7 miRNAs were one of the first miRNAs discovered in Caenorhabditis 
elegans (Ardekani and Naeini, 2010). Let-7s are highly conserved among 
invertebrates and vertebrates, including humans who have twelve let-7 genes 
encoding nine miRNAs (Zhang et al., 2007; Ardekani and Naeini, 2010). Several 
let-7 genes have been mapped to regions within the human genome that are 
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frequently altered or deleted in various cancers (Calin et al., 2004). This 
discovery has implicated let-7 as a tumour suppressors.  
 
Two well-defined let-7 targets are the oncogenes, Ras and high mobility group 
AT-hook 2 (HMGA2). Ras is a signal transducing GTPase that delivers signals 
from cell surface receptors to functional intracellular pathways, thus affecting cell 
proliferation, growth, cytoskeleton organization, cell movements and survival 
(Pylayeva-Gupta et al., 2011). As a result, active Ras mutants (H-Ras, K-Ras and 
N-Ras) are found within a variety of human cancers including pancreatic, colon, 
thyroid and lung carcinomas. Let-7s regulate the expression of Ras, and its 
mutants via 3’ UTR binding which inhibits translation. Thus, when functioning as 
a tumour suppressor, let-7 mediates the suppression of Ras and its cellular 
processes (He et al., 2007; Pylayeva-Gupta et al., 2011).  
 
HMG2A is a non-histone architectural transcription factor that alters DNA 
conformation, leading to direct transcriptional activation of a variety of genes that 
influence cell growth, differentiation, proliferation and survival (Wantanbe et al., 
2009). HMG2A is undetectable in normal adult tissue but is highly expressed in 
embryonic tissues, lung cancer and uterine leiomyomas (Wantanbe et al., 2009; 
Zhang et al., 2007). Studies reveal that the let-7s regulate HMG2A by 
destabilizing its mRNA through 3’-UTR binding (Zhang et al., 2007).  
 
The let-7 family of miRNAs regulate numerous genes not all of which are as well 
defined as HMG2A and Ras. Recent data indicates that let-7s play a much larger 
role in controlling cell proliferation than initially thought as they have been 
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shown to functionally inhibit numerous cell cycle regulators including c-myc, 
CDC25A, CDK6 and cyclin D2 (Worringer et al., 2014; Vaz et al., 2013). 
 
1.6.6 miRNAs as molecular markers 
The frequent deregulation of miRNAs in cancer makes them attractive new 
markers for cancer detection and monitoring. miRNAs can either serve as 
diagnostic, prognostic or predictive markers; they can also monitor therapy 
success. Studies have suggested that miRNAs can help to differentiate cancer 
from normal tissue, discriminate different tumours subtypes, characterize poorly 
differentiated tumours and identify tumours of unknown origin (Lu et al., 2005). 
The stability of miRNAs, provides an advantage in using them over other 
markers. Studies have shown that miRNAs can be stably expressed in degraded 
total RNA samples from human tissues (Karube et al., 2005), and they remain 
detectable in formalin-fixed, paraffin-embedded tissue (Arroyo et al., 2011; 
Yaman et al., 2008, 2011).  
 
miRNA measurements in body fluids, such as blood or urine, are crucial for 
diagnostic purposes because these are fluids that are more accessible as compared 
to tissue or organs (Chan et al., 2005). miRNAs are present in body fluids as free 
miRNAs in exosomes (Michael et al., 2010), associated with AGO2 proteins 
(Arroyo et al., 2011) or in circulating tumour cells (Zhang et al., 2011). Studies 
by Yaman et al., 2011 and Zhang et al., 2011 indicated that miR-141 and miR21 
circulating miRNAs, may serve as non-invasive markers in prostate cancer.  
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Lawrie et al., 2008, first reported the existence of circulating miRNAs in serum 
and their possibility to be developed as cancer markers. The mechanism of 
release and the roles of circulating miRNAs are still largely unclear. Recently, 
Skog et al., 2008 showed that the interaction between cells via mRNA and 
miRNA can be accomplished by microvesicle transfer, thus circulating miRNAs 
are proposed to be released from tumour cells in microvesicles to ensure 
communication with recipient cells in the surrounding microenvironment. 
Because circulating miRNAs might manipulate target cells, cell-free miRNAs 
might be not only serum markers for cancer and disease progression but also 
functionally relevant and therefore potential targets for novel therapy approaches 
(Brase et al., 2010). 
 
MiR-21 is one of the first miRNAs to be described as an oncomir. As most of the 
targets of miR-21 are tumour suppressors, miR-21 is associated with a wide 
variety of cancers including that of the breast, ovaries, cervix, colon, brain and 
prostate. Studies by Brase et al., 2011; Li et al., 2012 and Jackson et al., 2014 
showed that miR-21 expression in prostate cancer tissue and serum samples is 
significantly associated with the pathological stage of prostate cancer as well as 
lymph node metastasis.  
 
Brase et al., 2011 also examined miR-141 as a miRNA correlated with tumour 
progression in cancer. The study identified it as one of the miRNAs present at 
high levels in patients with malignant tumours when compared to PSA.  In the 
same study, miR-141 was also shown to distinguish between patients with 
metastatic prostate cancer and healthy controls. However, both miR-21 and miR-
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141 are implicated in other cancers apart from prostate cancer and thus may not 
be suitable diagnostic markers for the disease but rather have prognostic value. 
 
1.7 Bioinformatics as a tool for the detection of novel biomarkers  
Over the past years, major advances have been accomplished in the field of 
molecular biology and these have been linked with advances in high throughput 
technologies such as genomics, transcriptomics and proteomics (Emmett et al., 
2014) Furthermore, these technologies have brought forward an explosive amount 
of biological information which has led to the need for computerised databases to 
store, organise, and analyse the data (Martone et al., 2004; Benson et al., 2012).  
For this reason, the field of bioinformatics, or systems biology, which is the 
merging of the computational and biological science disciplines, has been an 
important tool for the organisation and analysis of the vast amount of biological 
data (Zhang et al., 2011). The main aim of bioinformatics is to find key biological 
information hidden amongst a mass of raw data to identify important trends and 
patterns which would eventually lead to novel biomarker discovery for both 
diagnostic and therapeutic purposes (Raza, 2012). Additionally, bioinformatics 
allows for the in silico simulations of complex disease physiologies, such as 
interactions between components, on their molecular level (Berman et al., 2013). 
Bioinformatics has presented ways in which data mining approaches can be used 
to filter valuable targets such as miRNA, genes, or proteins for the discovery of 
possible novel biomarkers for diseases (Sommer et al, 2010).  
 
 
 
 
 
42 
 
1.9 Role of bioinformatics in miRNA research  
Studies have shown that aberrantly expressed miRNAs are a hallmark of several 
diseases like cancer (Croce et al., 2009). miRNA expression has been shown to 
be associated with tumour development, progression and response to therapy, 
suggesting their possible use as diagnostic, prognostic and predictive biomarkers 
(Iorio and Croce 2012). Identifying miRNAs, their target genes, and their 
respective regulatory functions are important for understanding normal biological 
processes as well as understanding their various roles in disease development 
(Zhang and Verbeek, 2010; Liu et al., 2012; Fujiwara and Yada, 2013). 
Bioinformatics facilitates experimental validation of miRNAs and their target 
genes by producing statistically significant hypotheses from biological data that 
has been stored in databases, based on other biological experimental data (Liu et 
al., 2012). Potential target identification is based on the software’s algorithm. 
There are several miRNA-target prediction software tools publicly available 
(Fujiwara and Yada, 2013) which include TargetScan, and miRDB (Wong and 
Wang 2015). Possible targets are predicted based on the software’s prediction 
algorithms. The target prediction software as well as the other platforms used in 
this study will be discussed further in the next chapter. 
 
 
1.10. Study rationale 
The principal involvement of miRNAs in the aetiology and progression of many 
common diseases indicates these molecules are significant markers with potential 
use as diagnostic, prognostic and therapeutic tools. The discovery that miRNAs 
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are detectable and quantifiable in the circulation of diseased persons adds further 
validity to their potential as biomarkers of disease, both benign and malignant. 
The investigation of existing miRNA molecules coupled with the identification of 
novel miRNAs, and elucidation of their downstream targets, will provide a better 
understanding of their functional effects and thus provide greater insight into the 
complex and poorly understood mechanisms underlying diseases such as cancer. 
In PCa, the roles of miRNAs have become clear due to the understanding of the 
interactions between miRNAs and their targets and the resulting impact on 
prostate carcinogenesis. Thus the purpose of this study was to identify specific 
miRNAs as potential early diagnostic biomarkers in prostate cancer using a 
combination of in silico methods and molecular methods. Specific study aims are 
outlined as follows: 
1.) The in silico identification of specific miRNAs and their targets involved in 
prostate cancer progression, as well as categorization of gene networks these 
targets are involved in, and the implications of the identified miRNAs in cancer 
causing pathways. 
2.) Analyse expression profiles of identified miRNAs in prostate cancer cell lines as 
well as a panel of cancer cell lines including breast, liver, colon, lung and oral 
carcinomas using real time PCR (qRT-PCR). 
3.) Analysis of identified prostate miRNAs as potential early diagnostic biomarkers 
by investigating whether the panel of miRNA identified are PCa specific or 
generalised to several malignancies studied via the cell lines used in this work. 
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Chapter 2 
Identification of miRNAs as biomarkers for the detection of 
Prostate cancer (PCa) using an in silico approach 
 
2.1 Introduction 
The sequencing of the genomes of many organisms as well as the human genome 
brought about the availability of a large amount of genomic data.  In an attempt to 
make use of this vast wealth of data from the genome sequencing projects, new 
fields in molecular biology such as functional genomics, proteomics and 
metagenomics were established (Hancock et al., 2013).  
These fields attempt to answer questions about the function of DNA at the levels 
of genes, RNA transcripts, and protein products accomplished by the study of 
patterns of gene expression under various conditions (Raza, 2012). 
Advancements in technologies involved in these fields such as DNA and protein 
microarrays, have resulted in an explosion of large scale experimental and 
literature data. Thes data are stored in various repositories known as databases 
(Raza, 2012). These databases perform a myriad of functions such as the analysis 
of gene and protein expression and regulation, gene annotations, comparison of 
genetic and genomic data, as well as the simulation and modelling of DNA, RNA, 
and protein structures as well as molecular interactions in structural biology 
(Zhang et al., 2011). As a result, the past 15 years have seen an exponential 
increase in these databases (Raza, 2012).   
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These databases include public repositories such as the GenBank, a gene database 
hosted by NCBI (National Centre for Biotechnology Information) (Benson et al., 
2012) and the Protein DataBank (PDB), a protein database hosted by the 
Worldwide Protein Data Bank (Berman et al., 2003). There are also a number of 
private databases, many of which are hosted and used by biotech companies or 
research groups involved in gene mapping projects (Benson et al., 2012). In this 
study, a number of databases were used for various objectives including 
identifying the target genes of miRNAs implicated in prostate cancer and 
analysing the interaction of proteins encoded by these genes. 
 
2.2 Data mining 
The process of retrieving interesting patterns of information from the 
aforementioned databases is referred to as data mining. It can also be categorised 
as the extraction of information from different sources of published literature 
(Yang et al., 2009). Data mining has also been used to identify disease associated 
entities and to understand their roles in disease onset as well as progression. 
Because of the unprecedented growth of genomic data, data mining has become a 
field of interest as almost any new discovery or development about a gene, its 
pathways or protein it codes for is recorded in literature and consequently updated 
in databases.  Thus the goal of data mining is to filter that knowledge and to 
present the resulting information to a user in a concise, understandable format 
(Faro et al., 2012). 
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The use of computational tools in data mining to decipher biological data has 
resulted in new methods for biomarker and disease discovery, as well as disease 
pathway elucidation. An in-silico approach to target discovery for early diagnosis, 
understanding of disease and development of therapeutics can save considerable 
wet bench time. This approach can reveal important evidence for evolutionary 
and functional relationships between genes and proteins (Krallinger and Valencia 
2005). 
 
2.3 Pathway Analyses using mirPath tool in DIANA-TarBase 
version 7 
The DIANA-miRPath is a tool that performs miRNA pathway analysis, providing 
accurate statistics. It is available at the DIANA-TarBase database (DIANA 
miRPath version 7.0) accessible at http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=mirpath/index.  The tool is capable of 
combining results with merging and meta-analysis algorithms, performing 
hierarchical clustering of miRNAs and pathways based on their interaction levels, 
as well as being able to generate sophisticated visualization of results, such as 
dendrograms or miRNA versus pathway heat maps (Paraskevopoulou et al., 
2013). 
DIANA-miRPath hosts numerous novel features, extensions and optimizations, 
including: (1) the use of predicted interactions derived from DIANA-microT-
CDS (Vlachos et al., 2014) and TargetScan 6.2 (Hsu et al., 2014); (2) a 
significant extension to the annotation database, enabling the identification of 
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miRNAs controlling molecular pathways as well as the performance of miRNA 
function annotation using gene ontology (GO) terms (Xiao et al., 2009; 
Paraskevopoulou et al., 2013); (3) a new Reverse Search Module with 
unprecedented flexibility that can assist in (re)-discovering miRNAs with not yet 
identified functions; and (4) support for seven model species: H. sapiens, Mus 
musculus, Rattus norvegicus, Drosophila melanogaster, Caenorhabditis elegans, 
Gallus gallus and Danio rerio. 
 
The gene and miRNA annotations in DIANA-mirPath are derived from Ensembl 
(Paraskevopoulou et al., 2013) and miRBase (Vlachos et al., 2014), respectively.  
The miRNA: gene interactions are derived from the in silico miRNA target 
prediction algorithms: DIANA-microT-CDS and TargetScan 6.2, the latter 
operates in both Context+ and Conservation modes (Paraskevopoulou et al., 
2013). DIANA-microT-CDS is a highly accurate target prediction algorithm with 
target prediction in 3′ UTR and CDS mRNA regions. 
 
2.4 Target gene prediction 
Many studies have shown that miRNAs play an essential role in gene regulatory 
networks (Section 1.5.3) by controlling the expression of genes involved in 
important biological processes (Bartel, 2009). Thousands of miRNA genes have 
been identified, but the functions of most of these miRNAs remain unknown due 
to the lack of experimental and computational approaches to predict their exact 
target mRNAs (Agarwal et al., 2015). 
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miRNA functional characterization is currently a very active research field in 
biology, and there has been a rapid accumulation of miRNA knowledge in the 
past few years. Although a large quantity of existing data is certainly very helpful 
to guide future studies, it can at the same time make it challenging for miRNA 
researchers to quickly retrieve information relevant to their studies. Because of 
this, several miRNA databases have been established to systematically organize 
miRNA data (Grimson et al., 2007). The most prominent one is miRBase, which 
was set up to provide official nomenclatures to the miRNA research community 
(Griffiths-Jones et al., 2006). Although miRBase is a valuable source for 
providing standard miRNA nomenclature, it contains limited information on 
miRNA functional annotation. Thus, besides miRBase, a few other databases 
have been developed to focus more on miRNA function and consequently target 
prediction. Some examples of these databases include TargetScanHuman, 
miRDB, and PicTar. These databases host miRNA targets predicted by different 
computational algorithms (Krek et al., 2005; Grimson et al., 2007). However, 
common features of miRNA target prediction tools include, seed match 
conservation, free energy and site accessibility. This section introduces two 
databases for miRNA gene target prediction in humans, TargetScanHuman and 
miRDB which were used in this study to improve the robustness of the 
predictions. 
 
2.5. TargetScanHuman 
Early studies of target recognition revealed that near-perfect complementarities at 
the 5' end of a miRNA, the so-called "seed regions" at positions 2 to 8, are 
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primary determinants of target specificity (Bartel et al., 2004). These sites are 
called the canonical binding sites and binding happens through Watson and Crick 
base pairing (Agarwal et al., 2015). However, studies have also shown that 
binding these regions may not always be sufficient for gene repression (Grimson 
et al., 2007). 
 
TargetScanHuman is a web server that predicts biological targets of miRNAs by 
searching for the presence of conserved 8-mer, 7-mer and 6-mer sites that match 
the seed region of the 3’ UTR of a mRNA (Agarwal et al., 2015). It can be 
launched at http://www.targetscan.org/. TragetScanHuman not only predicts 
mRNAs that have the aforementioned conserved sites, it also considers the 
flanking sites of the seed region. A study by Grimson et al., 2007 found that 
effective binding sites reside within an AU-rich region.  Thus, TargetScanHuman 
takes advantage of this in its prediction algorithm (Agarwal et al., 2015).   
 
Additionally, an accurate ranking of the predicted targets for each miRNA is 
provided (Friedman et al., 2009). This ranking is based on either the probability 
of evolutionarily conserved targeting (Agarwal et al., 2015) or the predicted 
efficacy of repression calculated using cumulative weighted context ++ scores of 
the sites (Agarwal et al., 2015). Predictions are also ranked by their probability of 
conserved targeting (Friedman et al., 2009).  TargetScanHuman uses the miRNA 
ID information as a query to extract target gene information from all available 
experiments publicly available.  
 
 
 
 
 
50 
 
2.6 miRDB 
miRDB is a freely accessible online tool for miRNA target prediction and 
functional annotations (Wong and Wang, 2015).  It can be launched from 
http://mirdb.org. A feature of this platform is the MirTarget algorithm, which was 
developed by analyzing thousands of miRNA target interactions from high-
throughput sequencing experiments. Unlike TargetScanHuman, seed conservation 
is a consideration and not priority in miRDB. Seed match considerations are only 
in the 7-mer and 8-mer regions. miRDB is also different from existing miRNA 
target predicting databases. Firstly, its database design strategy is centred on 
mature miRNAs. If a miRNA has three pre-cursors in a genome, there are three 
different databases for it (Wang, 2008). Thus, there is no centralized place to 
present the miRNA functional annotations (Wang, 2008; Peterson et al., 2014). 
As mature miRNAs are the carriers of miRNA function, miRDB is designed to 
focus on them only to avoid database redundancy (Wang, 2008; Peterson et al., 
2014; Wong and Wang, 2015). Secondly, miRDB has a wiki editing interface for 
community-provided miRNA annotations (Wang, 2008; Wong and Wang, 2015). 
With the rapid progress on miRNA functional studies, it is challenging for any 
single team to keep track of all the latest developments in the field (Wong and 
Wang, 2015).  Thus, miRDB allows miRNA researchers to provide miRNA 
functional annotations and actively interact with each other (Wang, 2008). 
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2.7 Functional characterization of genes via DAVID 
DAVID (Database for Annotation, Visualization and Integrated Discovery) is a 
publicly available high-throughput annotation tool that maps a large number of 
genes to a list of associated Gene Ontology terms and statistically highlights 
genes that are highly enriched for those terms (Huang et al., 2009). This increases 
the potential to identify biological processes most pertinent to the biological 
phenomena under study. DAVID is available at https://david.ncifcrf.gov/ version 
6.7 (Jiao et al., 2012). 
Gene ontology (GO) is a major bioinformatics initiative to unify the 
representation of gene and gene product attributes across all species (Rancaglia et 
al., 2013). The gene ontology project specifically aims to: 1) maintain and 
develop its controlled vocabulary of gene and gene product attributes; 2) annotate 
genes and gene products, and assimilate and disseminate annotation data; and 3) 
provide tools for easy access to all aspects of the data provided by the project. It 
also enables functional interpretation of experimental data using the GO, for 
example via enrichment analysis (Gene Ontology Consortium, 2004).   
The gene ontology covers three domains: 1) Cellular component, the parts of a 
cell or its extracellular environment. 2) Molecular function, the elemental 
activities of a gene product at the molecular level, such as binding or catalysis 
and 3) Biological process, operations or sets of molecular events with a defined 
beginning and end, pertinent to the functioning of integrated living units such as 
cells, tissues, organs, and organisms (Gene Ontology Consortium, 2004; 
Rancaglia et al., 2013). 
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There are many functions performed by the DAVID platform including functional 
annotation, gene functional classification and gene ID conversion. For the 
purpose of this study, the functional annotation tool was employed. 
One tool DAVID has is the Functional Annotation Clustering tool which is a 
newly added feature to the DAVID Functional Annotation Tool (Huang et al., 
2009). This function uses a novel algorithm to measure relationships among the 
annotation terms based on the degree of their co-association genes to group the 
similar, redundant and heterogeneous annotation contents from the same or 
different resources into annotation groups (Huang et al., 2009). This reduces the 
burden of associating similar redundant terms and makes the biological 
interpretation more focused on a group level. The tool also provides a look at the 
internal relationship among the clustered terms. The clustered format is able to 
give a more insightful view about the relationships of annotations (Dennis et al., 
2003).  
 
2.8 Gene/protein interaction analysis via STRING 
Complete knowledge of all direct and indirect interactions  between  proteins  in  
a given cell  would represent  an  important  milestone  towards  a  
comprehensive description of cellular mechanisms and functions. Currently, to 
achieve this goal is elusive. However, considerable progress has been made; 
particularly for certain model organisms and functional systems (Madu and Lin, 
2010). At present, protein interactions and associations are annotated   at   various   
levels of detail via online resources, ranging from raw data repositories to highly 
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formalized pathway databases (Franceschini et al., 2013).  For many applications, 
a global view of all the available interaction data is desirable, including 
computational   predictions. 
One such online database that predicts protein-protein/gene interactions is 
STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) 
http://string-db.org/.  
STRING aims to provide a comprehensive, yet quality controlled collection of 
protein-protein associations for a large number of organisms (Snel et al., 2003). 
The associations are derived from high throughput experimental data, from the 
mining of databases and literature, and predictions based on genomic context 
analysis (Mering et al., 2005). STRING integrates and ranks these associations by 
benchmarking them against a common reference set, and presents evidence in a 
consistent and intuitive web interface. Importantly, the associations are extended 
beyond the organism in which they were originally described, by automatic 
transfer to orthologous protein pairs in other organisms, where applicable. 
STRING currently holds 730 000 proteins in 180 fully sequenced organisms 
(Mering et al., 2005). STRING has three unique features for protein interaction 
prediction (1) it provides uniquely comprehensive coverage, with over 1000 
organisms, 5 million proteins and more than 200 million interactions stored; (2) it 
is one of very few sites to hold experimental, predicted and inferred interactions, 
together with interactions obtained through text mining; and (3) it includes a 
wealth of accessory information, such as protein domains and protein structures, 
improving its day-to-day value for users (Franceschini et al., 2013). 
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2.9 Analysis of tissue-specific gene expression profiles via TiGER     
and GeneHub-GEPIS 
2.9.1 TiGER 
TiGER (Tissue-specific Gene Expression and Regulation) available at 
http://bioinfo.wilmer.jhu.edu/tiger/ is a database that contains tissue-specific gene 
expression profiles or expressed sequence tag (EST) data, cis-regulatory module 
(CRM) data, and tissue specific transcription factor interaction data  in 30 human 
tissues  for each gene contained within the database (Liu et al., 2008). At present 
the database contains expression profiles for 19,526 UniGene genes, 
combinatorial regulations for 7,341 transcription factor pairs and 6,232 putative 
CRMs for 2,130 RefSeq genes (Liu et al., 2008). 
 
The gene expression pattern for each UniGene is calculated based on the NCBI 
EST database. TiGER has identified and catalogued 7261 tissue-specific genes 
for 30 human tissues based on their expression enrichment and statistical 
significance. Thus, on average, each tissue expresses approximately 290 tissue-
specific genes (Yu et al., 2007).  
 
In addition to EST data, TiGER also identifies transcription factors (TFs) based 
on patterns of co-occurrence of pairs of DNA binding sites (Yu et al., 2007). 
TiGER predicts 9060 tissue-specific TF interactions, around 300 for each tissue 
(Yu et al., 2005). To evaluate these results, the database uses known interactions 
as positive controls due to the scarcity of tissue-specific interactions.  
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Cis-regulatory modules (CRMs) are a stretch of DNA usually about 100-1000 
base pairs in length where several transcription factors can bind (Davidson, 
2004). They are the central cis-elements that control gene expression (Istrail and 
Davidson, 2005). TiGER calculates the interaction strength between two 
transcription factor (TF) binding sites and then derives an empirical "potential 
energy" for each TF binding site (Yu et al., 2007). This results in energy profiles 
for the promoter sequences of tissue-specific genes. An energy level less than -1 
indicates the existence of a TF module (Liu et al., 2008). 
 
This development of computational methods for tissue-specific combinational 
gene regulation, based on transcription factor binding sites, CRMs and ESTs 
enables the platform to perform a large-scale analysis of tissue-specific gene 
regulation in human tissues. 
 
2.9.2 GeneHub-GEPIS 
GeneHub-GEPIS is a web application that performs digital expression analysis in 
human and mouse tissues based on an integrated gene database (Zhang et al., 
2007). It is available at http://share.gene.com/Research/genentech/genehub-
gepis/genehub-gepis-search.html. 
The platform calculates the normalized gene expression levels across a large 
panel of normal and tumour tissues, thus providing rapid expression profiling for 
a given gene. The Digital Expression Unit (DEU) is used as a measure of 
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expression profiles in comparison to normal tissue and cancer tissue. For a given 
gene in each tissue category, it is defined as the number of matching expressed 
sequence tag (EST) clones from a normalized library size of 1 million (Zhang et 
al., 2007). The backend GeneHub component of the application contains pre-
defined gene structures derived from mRNA transcript sequences from major 
databases and includes extensive cross-references for commonly used gene 
identifiers (Zhang et al., 2004: 2007). ESTs are then linked to genes based on 
their precise genomic locations as determined by the Genomic Mapping and 
Alignment Program (GMAP). In addition, the gene-centric design makes it 
possible to add several important features, including text-searching capabilities, 
the ability to accept diverse input values, expression analysis for microRNAs, 
basic gene annotation, batch analysis, and linkage between mouse and human 
genes (Zhang et al., 2007). 
 
2.10 Previous work 
A list of 13 miRNAs implicated in prostate cancer was generated in a parallel 
study, (Khan, 2015), using publicly available databases, MiRBase 
(http://www.mirbase.org/search.html) (Grifiths-Jones et al., 2006) and the Gene 
Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo) (Barrett et 
al.,2013).  Of the 13 miRNAs, 8 were carried forward in the parallel study and 
the remaining 5 were used in this study. 
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2.11 Aims and Objective 
This chapter aimed to identify putative miRNA biomarkers associated with 
prostate cancer as well as explore some predicted interactions and pathways these 
miRNAs are involved in. This is in an effort to identify putative genes as prostate 
cancer biomarkers in conjunction with the targeting miRNAs. The work outlined 
in this chapter was undertaken using in silico methods. 
The specific study objectives were: 
i) Predict and analyse participating pathways for the 5 identified miRNAs using 
DIANA-Tarbase.  
ii) To identify the genes targeted by the 5 miRNAs identified from the previous 
study using TagetScanHuman and miRDB. 
iii) Functionally annotate the miRNA targeted genes using DAVID and furthermore 
generating gene/protein interactions networks using STRING. 
iv) To perform an in silico expression analysis of the miRNA targeted gene using 
TiGER and GeneHub-GEPIS.
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2.12 Methodology 
 
Figure 2.1: Outline of the in silico methodology for prostate cancer miRNA biomarker discovery.
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2.12.1 Pathway Analyses using mirPath Tool in DIANA-TarBase 
Version 7 
Pathway analysis for this section of the study was achieved using the mirPath 
software tool (Vlachos et al., 2014) in the DIANA-TarBase database (DIANA 
miRPath version 7.0) accessible at http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=mirpath/index. 
This database (DIANA-miRPath) was used to determine the involvement and 
implication of the 5 miRNAs in cancer causing pathways and to further implicate 
them in the progression of PCa. The 5 miRNA were used as input into DIANA-
miRPath. The microT-CDS tool was used to search for gene pathways, with a p-
value threshold of 0.05 and micro-T threshold of 0.8 used as parameters. The 
resulting gene pathways were unionised and visualized as a heat map. 
 
2.12.2 Prediction of Target Genes for Identified Prostate Cancer 
miRNAs 
2.12.2 (a) miRNA Target Prediction with TargetScanHuman 
Each of the five miRNAs designated miR1, miR2, miR3, miR4, miR5, were used 
as input in the TargetScanHuman search box using the miRNA nomenclature; 
hsa-miR-1 to hsa-miR5 for the respective miRNAs. Human was selected as 
species of priority from which to search for target genes. The queries were 
entered one at a time for each miRNA. TargetScanHuman returned a list of the 
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top 100 predicted target genes for each miRNA, irrespective of site conservation, 
ranked by cumulative weighted context++ scores for each miRNA.  From each 
gene list obtained, only genes with a target prediction score of 80 % and above 
was selected for further analysis. 
 
2.12.2 (b) miRNA Target Prediction with miRDB 
Another online database used for target prediction was miRDB. As mentioned in 
section 2.3, two databases were used to improve the robustness of the predictions. 
Each of the five miRNAs was entered into the miRDB search box individually. 
From the drop down menu, human was chosen as the priority species from which 
targets were to be searched. The query was submitted using the ‘Go’ option. 
miRDB returned a list of predicted targets for each miRNA, from each gene list 
obtained, only genes with a target prediction score of 80 % and above were 
selected for further analysis. 
 
Duplicates were removed from the individual gene lists obtained from the two 
platforms. These lists were combined and duplications were removed in 
Microsoft Excel. The result was a gene list of 502 genes. All the genes were 
represented by their official gene symbols 
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2.12.3 Functional Characterization of Predicted Genes via 
DAVID 
The functional annotation of the 502 target genes identified was done using the 
Database for Annotation, Visualization and Integrated Discovery 
(https://david.ncifcrf.gov/summary.jsp) DAVID version 6.7 (Jiao et al., 2012).  
The gene list was copied and pasted into DAVID search box and the official gene 
symbol was selected as the unique gene identifier.. Annotations were limited by 
selecting for Homo sapiens, with the classification stringency set to medium. The 
“options” were set as follows; display, fold change and Bonferroni analysis. The 
list was then submitted for functional annotation clustering. Using the medium 
classification stringency for clustering, a total of 63 clusters were generated. 
Clusters generated were individually investigated to select clusters of genes that 
are involved in biological processes, present in the membrane region and that 
were involved in pathways that are known to play a critical role in the onset and 
progression of cancer. A total of 12 genes were produced from functional 
annotation in DAVID that corresponded to the selection criteria used. 
 
2.12.4 Literature Review of Genes 
Literature mining for each gene obtained from DAVID was performed. The 
following platforms (Uniprot, PolySearch, Google Scholar and GoPubmed) were 
used to search for abstracts or journal articles implicating the genes in cancer. 
Subsequent to these mining approaches, a final list of 9 putative genes was 
compiled. These were then cross-referenced back to the 5 miRNAs for their 
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involvement in prostate cancer. However, only 4 out of the 5 miRNAs had gene 
targets. The criteria used in selecting the final gene list after the enrichment in 
DAVID resulted in miR1 not being linked to a target gene. The gene list 
produced in DAVID was analysed for protein/gene expression analysis in 
STRING. 
 
2.12.5 Analysis of Gene/Protein Interaction Networks via 
STRING 
Gene IDs for the 9 genes, targeted by the 4 miRNAs implicated in prostate cancer 
were used as input for the generation of a gene network using the STRING DB 
Version 9. (Meiring, 2003; Franceschini et al., 2013). The 9 genes were used as 
driver genes to produce expression networks. To produce each of the expression 
networks, parameters were chosen as a follows: (i) a confidence level of 0.7, (ii) a 
network depth of 4 and (iii) restricting to show only the top 50 interactions 
between the 9 genes targeted by four miRNAs. 
 
2.12.6 Analysis of Tissue-Specific Gene Expression Profiles via 
TiGER 
Each of the 9 genes using their gene symbols was used as input into the “search 
box” option in the Geneview tool of TiGER to search for gene expression in 
prostate tissue. 
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2.12.7 Digital Expression Analysis via GeneHubGEPIS 
The 9 genes were submitted by inputting the official gene symbol of each gene 
into the “search box” option, selecting ‘human’ as target species after which, 
selecting the “enter” option.  
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2.13 Results and discussion 
2.13.1 Analysis of DIANA-TarBase generated pathways 
 
 
Figure 2.2 Association of the miRNAs in cancer causing related pathways. 
The strongest association is indicated by the red blocks. These have a log p-value 
-10≤. Intermediate association is indicated by the orange colour with a log p-
value between -9.4 and -4.9. The weakest association is shown by yellow blocks 
with a log p-value between -1.5 and -5.  
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DIANA-TarBase aims to catalogue the published experimentally validated 
miRNA:gene interactions (Vlachos et al., 2014). The process of cataloguing 
miRNA targets faces major challenges as there are large numbers of interactions 
which the identified genes as well as the miRNAs are involved in (Xiao et al., 
2009; Hsu et al., 2014). Thus an in silico approach is usually relied on to examine 
miRNA regulatory networks and their effects on molecular pathways. 
Figure 2.2 shows the association of miRNAs in cancer causing related pathways. 
The analysis was done using the online publicly available tool DIANA-TarBase 
version7.0 (http://www.microrna.gr/miRPathv2).  The figure represents a heat 
map of the 5 miRNAs. The analysis in DIANA showed that possible gene targets 
of miR1 are involved in cellular processes such as regulation of the actin 
cytoskeleton, glycerolphospholipid metabolism and lysine degradation.  
It has been well documented that cancer cells reprogram their metabolic pathways 
to meet their abnormal demands for proliferation and survival (Tennant et al., 
2010; Cairns et al., 2011). This is because they need a higher rate of metabolism 
to support their accelerated proliferation rate (Tennant et al., 2010; Cairns et al., 
2011). Studies by Menendez and Lupu 2007; Cairns et al., 2011; Zhang and Du, 
2012 have shown that altered lipid metabolism has been recognized as a common 
property of malignant cells. Because lipid metabolism in cancer cells is regulated 
by common oncogenic signalling pathways (Chunfa and Freter, 2012), and is 
believed to be important for the initiation and progression of tumours (Menendez 
and Lupu 2007), miR1, miR3 and miR5, predicted to be involved in this pathway, 
may be good indicators of the onset of cancer.  
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One of the predicted pathways that miR2 is involved in is the inositol phosphate 
metabolism pathway (Figure 2.2). Members of this pathway regulate cell 
proliferation, migration and phosphatidylinositol-3-kinase (PI3K)/Akt signalling 
(Yu et al., 2009). A recent study, (Tan et al., 2015) has shown that genes in this 
pathway are frequently dysregulated in cancer. The study found that gene 
dysregulation in this pathway was significantly associated with a risk of lung, 
breast, prostate and bladder cancers. 
 
2.13.2 miRNA target prediction 
 
Two publicly available target search databases, TargetScan and miRDB were 
used as platforms to identify genes associated with the five miRNAs. 
 
Table 2.1: Representation of the number of target genes identified. 
Database Name  # of target genes 
identified 
miRDB 
 
1076 
TargetScanHuman 1502 
 
 
The target genes obtained from the two databases were prioritized using the 
following criteria; (a) only the genes with a prediction score of 80 % and above 
were taken for further analysis, (b) gene lists with more than 800 targets were 
excluded, (c) duplications were eliminated in Excel.  
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Table 2.1 shows the number of target genes identified by the two different 
databases after applying the above criteria. The list from TargetScanHuman was 
1502 genes and miRDB produced 1076 genes. (A combined list of gene targets 
from TargetScan and miRDB can be found in appendix A). There was a 
difference of 426 genes between the two databases used. This 28 % difference in 
the number of genes targeted by the miRNAs could be explained by the 
properties (target prediction algorithms) of both databases. As mentioned in 
section 2.5, miRDB avoids database redundancy (Wang, 2008; Peterson et al., 
2014; Wong and Wang, 2015) and only considers seed matches in the 7-mer and 
8-mer regions, whilst TargetScanHuman includes 6-mer regions in addition to 7-
mer and 8-mer regions (Wang, 2008).  The two gene lists were combined and 
duplicates were removed, resulting in a final gene list of 502 genes.  
 
2.13.3 Functional Annotation via DAVID 
The 502 genes prioritized in section 2.12.1 were used as input into DAVID for 
functional annotation and analysis. A classification stringency of medium in was 
employed in DAVID. The output was a total of 150 genes in 86 clusters. DAVID 
categorized the gene products into three Gene Ontology (GO) groups, namely; 
Cellular Component (CC) Biological Process (BP) and Molecular Process (MP), 
as seen in figures 2.3, 2.4 and 2.5 respectively. 
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Figure 2.3: Functional characterizations of miRNA target genes under cellular component using DAVID. The blue bars 
represent the number of genes associated with the specified GO term.  
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Figure 2.4: Functional characterizations of miRNA target genes under biological processes using DAVID. The blue bars 
represent the number of genes associated with the specified term.  
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Figure 2.5: characterizations of miRNA target genes under molecular function using DAVID. The blue bars represent the 
number of genes associated with the specified GO term.  
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Table 2.2: miRNA target genes involved in the cellular component domain. 
Gene 
 
Cellular Component 
MNT - 
AFAP1 Integral to plasma membrane, cell fraction  
BIRC2 Cytoplasm membrane bound vesicle, cell 
fraction 
LIG4 Integral to plasma membrane 
YWHAZ Cell fraction, vesicle, membrane bound vesicle,   
TNFSF15 Extracellular region, integral to plasma 
membrane  
TNFSF13B Extracellular region, integral to plasma 
membrane, extracellular region 
CTNND1 Cell fraction, membrane bound vesicle 
FOXC1 Nuclear chromatin 
 
Table 2.2 shows the breakdown of the 9 target genes involved in the cellular 
component. From figure 2.3, it can be seen that about 23 genes function in the 
extracellular region. Two of the target genes have been found to function in 
extracellular region, namely TNFSF13B and TNFSF15; they constitute 8.7 % of 
the total number of genes.  The gene MNT did not have a cellular component 
function. AFAP1, TNFSF15, TNFSF13B and LIG4 constitute 15.4 % of the total 
genes characterized in DAVID. BIRC2 makes up 9 % of the total genes coding 
for proteins functioning as cytoplasm membrane vesicles (figure 2.3). YWHAZ 
and CTNND1 make up 6 % of the genes coding for proteins found in the cellular 
fractions. FOXC1 makes up 3 % of the total number of genes involved in nuclear 
chromatin functions.  
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Table 2.3: miRNA target genes involved in the biological process domain 
 
Gene 
Biological Process 
MNT Regulation of transcription, regulation of apoptosis, 
immune response 
AFAP1 - 
BIRC2 Response to endogenous cell death, apoptosis, negative 
regulation of apoptosis 
LIG4 Negative regulation of apoptosis,  
YWHAZ Immune response, protein localization 
TNFAF15 Negative regulation of apoptosis 
TNFAF13 Negative regulation of apoptosis, immune response, 
CTNND1 Protein localization 
FOXC1 Regulation of apoptosis 
 
Table 2.3 shows the breakdown of the 9 target genes involved in the biological 
process domain.  The biological process ontology constituted the greater number 
of the gene functions. The genes MNT and FOXC1 made up 7 % of the total 
genes involved in regulation of apoptosis. BIRC2, LIG4, TNFAF15 and 
TNFAF13B made up 20 % of genes involved in negative regulation of apoptosis. 
The genes YWHAZ and CTNND1 constituted 4 % of the genes involved in 
protein localization (figure 2.4). The gene AFAP1 did not have any predicted 
biological process function. 
 
Table 2.4: miRNA target genes involved in the molecular function domain. 
Gene 
 
Molecular Function 
MNT Transcription factor binding, transcription regulator 
AFAP1 Protein binding 
BIRC2 Metal ion binding  
LIG4 Metal ion binding, nucleoside binding 
YWHAZ Transcription factor binding 
TNFSF15 Tumour necrosis factor 
TNFSF13B Tumour necrosis factor 
CTNND1 Protein binding 
FOXC1 Transcription regulator 
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Table 2.4 shows the breakdown of the 9 target genes involved in the molecular 
function domain of the gene ontology. It can be seen from figure 2.5 that 20 
genes are involved in protein binding.  Two of the target genes are found to be 
represented in that number, namely CNTDD1 and AFAP1. FOXC1 and MNT 
constitute two out of 10 of the transcription regulator genes. The genes TNFSF15 
and TNFSF13B are the only genes that code for the tumour necrosis factor.  LIG4 
and BIRC2 represent 66 % (2 out of 30) genes involved in metal ion binding 
(figure 2.5).  The gene YWHAZ constitutes 6.7 % of the genes coding for 
transcription factor binding. 
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Table 2.5: Representation of the miRNAs and their identified gene targets from 
DAVID. 
 
miRNA 
Confidence 
% 
 
Target (Gene) 
 
Gene description 
miR4 96 TNFSF15 Tumour necrosis factor 
(ligand) superfamily, 
member 15 
 
miR4 
miR3 
80 LIG4 Ligase IV, DNA, ATP-
dependent 
miR4 99 FOXC1 Forkhead box C1 
miR5 97 YWHAZ Tyrosine 3-
monooxygenase/ 
tryptophan  5-
monooxygenase 
activation protein, zeta 
polypeptide 
 
miR5 88 TNFSF13B Tumour necrosis factor 
miR4 
miR2 
98 
83 
 
AFAP1 
(AFAP) 
Actin Filament 
Associated Protein 
miR4 83 CTNND1 (E-cadherins) cell 
malignancy 
miR4 87 BIRC2 Apoptotic suppressor 
 
miR3 80 MNT MAX binding protein 
 
One feature of the functional annotation tool in DAVID is to give predictions on 
the localisation of proteins encoded by the input genes. For purposes of this 
study, emphasis was placed on genes with proteins localised on the cell surface. 
Figure 2.3 depicts miRNA targets strongly associated with membrane and 
membrane bound proteins. In the process of tumour development, or invasion, 
some proteins involved in cell-cell adhesion or cell movement lose their adhesive 
properties and are shed into the surrounding environment (Hanash, 2011) finding 
their way into biological fluids, such as saliva, blood and urine. This makes them 
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good targets as biological markers for therapeutics and diagnostics. Other 
important aspects that were taken into consideration when prioritizing the gene 
list were the processes they are involved in. Genes involved in biological 
processes such as regulation of apoptosis, secretion and immune response were 
prioritized, figure 2.4. These genes were considered significant as apoptosis is 
important in cancer development. Studies have shown that some oncogenic 
mutations disrupt apoptosis, leading to tumour initiation, progression or 
metastasis (Lowe and Lin, 2000). Conversely, compelling evidence indicates that 
other oncogenic changes promote apoptosis, thereby producing selective pressure 
to override apoptosis during multistage carcinogenesis (Su et al., 2015). 
Figure 2.5 shows that 30 % of the target genes are involved in transporter 
membrane activity. Recent studies have shown that plasma membrane transporter 
proteins play an important role in taking up nutrients into and effluxing 
xenobiotics out of cells to sustain cell survival (Williams, 2014). In the last 
decade, it has been reported that many transporters are differentially up-regulated 
in cancer cells compared to normal tissues, suggesting that the differential 
expression of transporters in cancer cells may become a good target for diagnostic 
markers for cancer therapy.  
The outcome of functional annotation using DAVID, coupled with literature 
mining was a list of 9 genes. A number of these genes, depicted in table 2.5, have 
been implicated in cancer (YWHAZ, FOXC1 and TNFSF13B) as well as prostate 
cancer, (MNT) (van Rooij, 2011; Dedeoğlu, 2014; Stokowy et al., 2014; Uso et 
al., 2014; Dedeoğlu, 2014). The remaining genes do not appear in literature as 
having been validated as prostate cancer biomarkers or connected to the disease.  
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2.13.4 Gene/Protein Interaction Analysis via STRING 
The 9 genes were used as input into STRING Version 9 to visualize protein 
expression networks as described in section 2.12.5 Figures 2.4 and 2.5 show the 
results of the analysis. Figure 2.12.5 shows that there was an association between 
TNFSF15 and TNFSF13B which code for the human tumour necrosis factor 
ligand superfamily member proteins, which are also known as proliferation-
inducing ligands. Both these two genes may play a key role in the development of 
B-cells (Boss et al., 2006) and plasma cells in the bone marrow (Matthes et al., 
2011). They also function in the development of human tumours (Zhao et al., 
2014). TNFSF13B expression is related to the progression of several types of 
carcinomas (Moreaux et al., 2009; Pelekanou et al., 2011) including renal cell 
cancer, (Pelekanou et al., 2011), breast cancer, (Zhao et al., 2014; Moreaux et al., 
2009) and lung cancer (Lin et al., 2012). 
 
It can be seen in figure 2.4 that TNFSF15 and TNFSF13B are both linked to 
LIG4 by the apoptotic suppressor BIRC2.  BIRC2 is a member of the inhibitor of 
apoptosis family of proteins and plays a pivotal role in regulation of nuclear 
factor-κB (NF-κB) signalling and apoptosis (Gyrd Hansen et al., 2010). Up-
regulation of BIRC2 has been frequently detected in lymphoid malignancies 
(Gyrd Hansen et al., 2010). A recent study (Yamato et al., 2015) showed that up-
regulation of BIRC2 is evident in a wide range of epithelial tumours such as lung 
tumours. 
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Figure 2.6: Protein Network Visualization generated by 
STRING. The interactions of the 9 miRNA targeted genes 
clustered together. The genes are represented by the nodes and the 
different line colours represent the types of evidence for the 
association. 
Figure 2.7: Protein Network Visualization generated by 
STRING. The interactions of the 9 miRNA targeted genes in in 
association with other genes. The genes are outlined in the black 
boxes. 
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The gene LIG4 encodes the protein DNA ligase that joins single-strand breaks in 
a double-stranded polydeoxynucleotide in an ATP-dependent reaction (Francis et 
al., 2014; Xie et al., 2014). Thus this protein is essential for recombination and 
DNA double-strand break repair. Dys-regulation of this gene by miRNAs may 
influence DNA repair ability, thus altering genetic stability and resulting in 
carcinogenesis. The genes AFAP1, CTNND1, YWHAZ and FOXC1 are linearly 
connected. AFAP1 is thought to encode a protein that is a potential modulator of 
actin filament integrity which responds to cellular signals. One of the Hallmarks 
of cancer is cell signalling, with cancer cells being self sufficient with regards to 
needing external signals to grow and divide, or insensitivity to anti-growth signals 
(Weinberg and Hanahan, 2000; Hanahan, 2011). Perhaps dys-regulation in this 
gene may result in cell signalling insufficiency or insensitivity. However, further 
studies would have to be done to prove this.  
The FOXC1 gene belongs to the forkhead family of transcription factors which is 
characterized by a distinct DNA-binding forkhead domain. The specific function 
of this gene has not yet been determined. However, a recent study implicated it in 
brain metastasis in breast cancer (Ray et al., 2010; Sizemore et al., 2012). The 
MAX binding protein MNT did not have any connections to the other genes.  
Figure 2.7 shows the predicted interactions of the 9 miRNA target genes with 
each other as well as with other genes. The 9 genes of interest are outlined in 
solid boxes. Thus, the 9 candidate genes are involved in metabolic and cellular 
pathways with not only each other but with other genes. The associations are 
based on the co-occurrence of proteins on metabolic maps in the KEGG database 
(von Mering et al., 2003). Proteins that occur on the same metabolic KEGG map 
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are presumed to be functionally interacting. The different coloured lines represent 
evidence for the association. STRING, displays a score of confidence for each 
association between proteins (low confidence: scores <0.4; medium: 0.4 to 0.7; 
high: >0.7). The higher the score, the more evidence for the association recorded 
by STRING (Eisen et al., 1998; von Mering et al., 2003; Franceschini et al., 
2013).  Some genes have more than one association. They have a combined score 
which is close to one. Thus, the more combined associations between genes, the 
more evidence for the interaction. (Franceschini et al., 2013). Upon visualization 
of predicted interaction networks of BIRC2 (figure 2.7), it can be seen that it has 
many associations. This shows that it is an important protein to the network. The 
more interactions a protein has in a network, the more important that protein is to 
the network as many other proteins rely on it in their functioning (Tomaic et al., 
2008). BIRC2 is connected to CASP3, DIABLO, RAF1, TRAF1 and TRAF2. It 
is connected to these genes by 3 lines of evidence, indicating more associations 
and thus higher confidence (Tomaic et al., 2008). The family of TRAF genes 
encode proteins that are receptor associated factors. They are involved in the 
regulation and response to apoptosis (Inoue et al., 2000; Potter et al., 2007). 
DIABLO is a mitochondrial protein that potentiates some forms of apoptosis 
(Adrain et al., 2001; Martinez-Ruiz et al., 2008). CASP3 encodes proteins in the 
family of caspases. These are endoproteases that provide critical links in cell 
regulatory networks controlling inflammation and cell death. Thus CASP 3 is an 
apoptosis related cysteine peptidase (Mcllwain et al., 2013). Studies by Soung et 
al., 2004 and Chen et al., 2008 found that alterations in this gene may lead to 
human tumourigenesis.  
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Upon visualization of predicted interaction networks of YWHAZ, it was observed 
that it has two interactions with FOXC1, two with CTNND1, two with RAF1 and 
one interaction with CASP3. This is a total of 7 interactions. This shows that it is 
an important protein, central to this particular network.  
 
2.13.5 Tissue Specificity Expression Analysis via TiGER and 
GeneHub-GEPIS 
The 9 genes were subjected to cross cancer tissue specific analyses in TiGER and 
GeneHub-GEPIS (section 2.12.6-7). Figures 2.8 to 2.10 give a graphical display 
of 3 genes and their expression in prostate tissue for both databases. Data on the 
remaining 6 genes can be found in Appendix A. GeneHUB-GEPIS database 
compares expression of the gene between cancerous and normal tissue.  
A detailed understanding of how genes are expressed and regulated in different 
tissues can help elucidate the molecular mechanisms of tissue development and 
function. The approximately 25,000 genes (Liu et al., 2008) in the human genome 
demonstrate dramatic diversity in terms of expression levels, both temporally and 
spatially (Bartel, 2009). Despite this diversity, the expression of all genes is 
controlled by a relatively small number (less than 2,000) of transcription factors 
(Liu et al., 2008). Thus gene expression regulation also depends heavily on 
miRNAs (Bartel, 2009).  Therefore, a database dedicated to comprehensive 
information about tissue-specific gene regulation is a desirable tool in expression 
studies.  
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The TiGER results for the MNT gene show that it is preferentially expressed in 
prostate tissue (Figure 2.8 A). The GeneHub-GEPIS results for MNT show a 
DEU value of 94.6 in over-expressed cancerous prostate cells when compared  to 
the normal prostate tissue (Figure 2.8 B). This figure is higher than the normal 
tissue expression and MNT’s over-expression in any other tumour tissue. This 
gene is targeted by miR3, thus it is a potential biomarker for prostate cancer 
detection. MNT codes for a protein that is a transcriptional repressor and an 
antagonist of Myc-dependent transcriptional activation and cell growth 
(Montagne et al., 2008). This could explain its over-expression in prostate cancer 
tissue.  
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Figure 2.8: Expression profile for MNT from TiGER (A) MNT is preferentially expressed in the prostate with an 
expression enrichment value greater than 2. GeneHUB-GEPIS (B). Normal tissue expression is shown in blue; over 
expression in tumour tissue is shown in yellow. 
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Figure 2.9: Expression profile for YWHAZ from TiGER (A) YWHAZ is preferentially expressed in the tongue with an expression 
enrichment value greater than 2.5. Expression in prostate tissue is between 1 and 0.5.  GeneHUB-GEPIS (B). Normal tissue expression 
is shown in blue; over expression in tumour tissue is shown in yellow. 
B 
A 
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Figure 2.9 show expression profiles of the gene YWHAZ, targeted by miR5. 
TiGER results indicate that it is preferentially expressed in the tongue followed 
by the bladder with an expression enrichment of about 2.8 and 2.4 respectively.  
The GeneHub-Gepis results show a DEU of 588.53 in prostate tumour tissue. 
Thus, YWHAZ is over-expressed in prostate tumour when compared to normal 
prostate tissue. However, over-expression in eye tumours is greater at 950.77 
DEUs. Therefore YWHAZ may not be a good biomarker specific to prostate 
cancer detection, further experimental evaluation is required. 
 
There was no data present for AFAP and TNFSF15 in TiGER, figures 2.15 and 
2.16 (appendix A).  However, there was data on tumour and normal tissue 
expression for AFAP1 in GeneHub-GEPIS. The expression profile in GeneHub-
GEPIS showed that it is under-expressed in prostate tumours when compared to 
the normal prostate tissue. 
 The lack of data for AFAP1 and TNFSF15 in TiGER could be as a result of lack 
of data for the particular genes in the database (not including the current data) or 
it could indicate that gene expression in tissues is not well documented for both 
the genes. The TNFSF15 gene targeted by miR2 and miR4 belongs to the tumour 
necrosis factor ligand family, as discussed earlier (section 2.13.3). It acts as an 
autocrine factor to induce apoptosis in endothelial cells (Michelsen et al., 2009). 
It has been reported to be abundantly expressed in endothelial cells. Thus, 
dysregulation can result in any number of cancers.  
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Figure 2.10: Expression profile for LIG4 from TiGER (A) LIG4 is preferentially expressed in muscle tissue with an expression 
enrichment value of about 4.5. There is no expression recorded in prostate tissue.   GeneHUB-GEPIS (B). Normal tissue 
expression is shown in blue; over expression in tumour tissue is shown in yellow. 
 
B 
A 
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From the results of the expression profiling in TiGER and GeneHub-GEPIS, there 
is evidence that genes targeted by the 5 miRNAs are expressed in prostate tissues. 
However, some of the genes are preferentially expressed in other tissues, with 
some genes such as LIG4 (figure 2.10) not having any expression at all in neither 
the normal prostate tissue nor the prostate tumour tissue. There could be three 
reasons for this, the gene is not expressed in the prostate tissue, the databases 
used are lacking information on this gene or thirdly, there is currently no 
experimental validation of LIG4 expression in prostate tissue.   
 
2.14. Conclusions and Summary 
 
It has been shown that miRNAs are involved in carcinogenesis (Croce et al., 
2008) via regulation of gene expression (de Bock et al., 2010). Recognition of 
miRNAs that are differentially expressed between tumour tissues and normal 
tissues may help to establish the apparent pathogenic role of miRNAs in cancers 
(Lu et al., 2005; Karube et al., 2010; Zhang et al., 2007). Investigations (Croce et 
al., 2008) have demonstrated that almost all cancers have alternative miRNA 
expression profiles when compared to their adjunct normal tissues. These cancer 
types include lung cancer, leukaemia, brain cancer, prostate and breast cancer (de 
Bock et al., 2010), which together have caused the majority of cancer related 
deaths in the past decades (CDC, 2014).  
 
In this study, putative miRNA biomarkers for prostate cancer were identified. A 
combination of biological data mining, text mining and in silico gene enrichment 
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techniques proved to be effective in classifying genes targeted by miRNAs and 
linking them to cancer.  An analysis of predicted miRNA pathways in DIANA 
showed that they are involved in metabolic processes that that are important in 
cancer progression. Thus, it can be investigated further if they are involved in 
prostate cancer via qRT-PCR expression analysis. 
The gene targets of the miRNAs annotated in DAVID showed that they are 
involved in the cellular component, biological processes and molecular function 
gene ontology domains. In these domains it was found that the genes code for 
proteins involved in various processes and cell functions whose dys-regulation 
could lead to cancer. Some of the genes such as MNT and FOXC1 were found to 
code for proteins that are involved in regulation of apoptosis. LIG4, AFAP1 and 
CTNND1 code for proteins integral to the plasma membrane. BIRC2, TNFSF13B 
and TNFSF15, were found to code for proteins that are involved in negative 
regulation of apoptosis. YWHAZ codes for genes involved in immune response.  
STRING results indicated that the genes are involved in interaction networks with 
each other as well as other genes. It was noted that the genes are connected to 
CASP3, DIABLO, RAF1, TRAF1 and TRAF2 which have demonstrated roles in 
apoptosis. It was also found that BIRC2 is the most connected gene in the gene 
list. Thus it is an important part of the gene network as it connects many genes 
via its associations.   
Tissue specificity expression analysis in TiGER revealed that MNT is 
preferentially expressed in prostate tissue. Results from GeneHUb-GEPIS 
showed that the gene was over expressed by a DEU of 94.6 in prostate tissue 
when compared to the normal tissue. The analysis also showed that, YWHAZ, 
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FOXC1 and TNFSF13B, were all found expressed in prostate tissue. LIG4 and 
TNFSF15 did not express in prostate tissue. AFAP1 did not show expression in 
prostate from the TiGER database. However, GeneHub-GEPIS showed that it is 
under-expressed in prostate tumours when compared to the normal prostate 
tissue. 
 
 
 
 
 
89 
 
Chapter 3 
3. Molecular Validation of miRNAs as Putative Biomarkers for 
the Early Detection of Prostate Cancer 
 
3.1 Introduction 
It is well documented that miRNAs are involved in gene regulation (Lagos-
Quintana et al., 2001; Bartel, 2004; Ardekani and Naeini, 2010). This is done 
through binding to target mRNA, thereby altering protein expression. As 
discussed in section 1.6.3, the binding of miRNA to the mRNA can inhibit 
protein translation or accelerate the process of deadenylation causing an mRNA 
to be degraded (Melo and Melo, 2014). Because of their function, miRNAs have 
played a vital role in disease pathogenesis and have potential as biomarkers and 
therapeutic agents (MacFarlane and Murphy, 2010; Yang et al., 2011; Worringer 
et al., 2014). 
Currently, routine diagnostic methods for the early detection of PCa include 
digital rectal examination (DREs) and prostate-specific antigen (PSA) testing 
(American Joint Committee on Cancer, 2012; CANSA, 2015). The PSA test is 
nonspecific, due to the fact that elevated PSA levels have been measured in 
benign prostatic hyperplasia (BPH), infection, and/or chronic inflammation 
(Heidenreich et al., 2011; Basch et al., 2012). Thus, testing for PSA may lead to 
confounding outcomes. Other blood based biomarkers including the human 
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glandular kallikrein 2 (hK2) and urokinase plasminogen activator (uPA) and its 
receptor (uPAR), have been studied alone or in combination with PSA and 
suggested for diagnosis, staging, prognostics, (Karazanashvili and Abrahamsson, 
2003; Ishiguro et al., 2009; Nguyen et al., 2014) and monitoring of prostate 
cancer (Nguyen et al., 2014). However, because of the diverse nature of prostate 
cancer and its presentation in patients (Karazanashvili and Abrahamsson, 2003), 
there is an urgent need to identify additional biomarkers for enhanced prediction 
of disease progression and prognosis to aid in clinical decision making with 
respect to treatment options. 
 
miRNAs have many required features of good biomarkers, they are stable in 
various bodily fluids, the expression of some miRNAs is specific to tissues or 
biological stages (Sita-Lumsden et al., 2013; Moldovan et al., 2014), and the 
level of miRNAs can be easily assessed by various methods of gene expression 
profiling such as the Polymerase Chain Reaction (PCR) (Derveaux et al., 2010). 
The changes of several miRNA levels in plasma, serum, urine, and saliva have 
already been associated with different diseases (Hanke et al., 2009; Fabbri 2010). 
For example, the ratio of miR-126 and miR-182 in urine samples can be used to 
detect bladder cancer (Hanke et al., 2009), and decreased levels of miR-125a and 
miR-200a in saliva is associated with oral squamous cell carcinoma (Ng et al., 
2009).  
 
Gene expression analysis is increasingly important in various biological research 
fields and understanding the patterns of expressed genes is expected to provide 
insight into complex regulatory gene networks and can lead to identification of 
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genes implicated in disease. Quantifying gene expression levels can yield 
valuable clues about the function of a gene, for instance, accurate measurements 
of gene expression can identify the type of cells or tissues where particular genes 
are expressed, reveal individual gene expression levels in defined biological 
states and detect alterations in gene expression levels in response to specific 
biological stimuli (Fraga et al., 2008).  
 
3.1.1 Quantitative real-time PCR (qRT-PCR)  
The quantitative real-time polymerase chain reaction (qRT-PCR) has recently 
become the most widely used technique in modern molecular biology (Derveaux 
et al., 2010). This technique depends on the fluorescence-based detection of 
amplicon DNA and permits the kinetics of PCR amplification to be monitored in 
real time, making it possible to quantify nucleic acids with ease and precision 
(Guescini et al., 2008). Quantitative real-time PCR (qRT-PCR) has become a 
very versatile technique to examine expression changes of one or more genes of 
interest in various pathological states such as cancer. This method offers a broad 
range of advantages over standard methods such as the Northern blot and semi-
quantitative PCR due to its specificity, sensitivity, simplicity, low cost and high-
throughput nature (Derveaux et al., 2010). 
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3.1.2 Quantification Strategies in qRT-PCR 
There are two strategies used to quantify gene expression in qRT-PCR; absolute 
quantification and relative quantification. Absolute quantification relies on a 
standard curve which is generated by using a serially diluted sample of known 
concentration. The log of these dilution concentrations are plotted against the 
crossing points (Cp).  
The crossing point (Cp) is the cycle at which fluorescence achieves a defined 
threshold (Taylor, 2010). It corresponds to the cycle at which a statistically 
significant increase in fluorescence is first detected (Pabinger et al., 2009). The 
Cp value decreases linearly with an increase in target quantity. Thus, Cp values 
can be used as a quantitative measure of the input target number (Heid et al., 
1996). 
 
Relative Quantification compares the levels of two different target sequences in a 
single sample, such as the target gene of interest and another gene; and expresses 
the final result as a ratio of these targets (van Peer et al., 2012). For comparison 
purposes the second gene is a reference gene that is found in constant copy 
numbers under all test conditions (Yuan et al., 2006). This reference gene, which 
is also known as endogenous control, provides a basis for normalizing sample-to-
sample differences (Heid et al., 1996). 
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3.1.3 Aims and Objectives 
This section of the study aimed to validate the 5 miRNAs identified by in silico 
expression analysis in chapter 2 using molecular methods. Specific objectives are 
outlined as follows; 
1.) Growth of a prostate cancer cell line, a benign prostate hyperplasia cell line, other 
cancer cell lines as well as non-cancerous cell lines including a normal prostate 
cell line from which miRNA was extracted. 
2.) Extraction of miRNA and synthesis of cDNA 
3.) Molecular expression profiling of the 5 miRNA (cDNA) via Real-time 
Polymerase Chain Reactions (qRT-PCR) in all cell lines. 
 
3.2 Materials and Methods 
 
Reagents and suppliers. 
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Table 3: General reagents and suppliers 
Reagent  Supplier 
Dulbecco's Minimal Essential 
Medium (DMEM)  
 
Lonza 
Dulbecco's Minimal Essential 
Medium (DMEM) 
F12 
 
Lonza 
Roswell Park Memorial Institute 
Medium (RPMI) 1640  
 
Lonza 
Dimethyl Sulphoxide (DMSO)  
 
Sigma 
Fetal Bovine Serum (FBS) 
 
Lonza 
Phosphate Saline Buffer (PBS)  
 
Lonza 
Trypsin Lonza 
β-mercaptoethanol Sigma 
KAPA SYBR® FAST qRT-PCR 
Kit 
KAPABiosystems 
RNA isolation kit Nucleospin®  Macherey-Nagel 
Nuclease free dH2O  Merck 
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3.2.1 Cell Culture 
Cell lines used in the study are depicted in table 3.1.  The cell lines that were used 
in the course of this research were purchased from American Type Culture 
Collection (ATCC). The PNT1a cell line (passage 4) was obtained from Luiz 
Zerbini of the International Centre for Genetic Engineering and Biotechnology 
Cape Town (ICGEB). All cell lines are epithelial and adherent except the BPH1 
which is epithelial but non-adherent. 
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Table 3.1: Cell lines used to investigate the specificity of the miRNAs in cancer. 
Cell 
line 
Tissue Description Growth 
medium 
 
 
PNT1a 
 
Prostate Non-cancerous  
prostate 
epithelial cell 
line 
RMPI, 
PenStrep 10 % 
FBS 
LNCaP 
 
Prostate AR-sensitive 
prostate 
carcinoma 
RPMI, 
PenStrep 50 % 
FBS 
BPH1 
 
Prostate Benign prostate 
hyperplasia 
RPMI, 
PenStrep 10 % 
FBS 
A549 
 
Lung- 
Alveolar  
Lung epithelial 
carcinoma 
DMEM, 
PenStrep 10 % 
FBS 
HEPG2 
 
Liver  Hepatocyte 
epithelial 
carcinoma 
DMEM, 
PenStrep 10 % 
FBS 
MCF12 
 
Breast Non-cancerous 
Breast cell line 
DMEM/F12, 
PenStrep 10 % 
FBS, 
Hdyrocortisone, 
EGF, Insulin  
MCF7 Breast- 
pleural 
effusion 
Breast 
adenocarcinoma 
DMEM, 
PenStrep 10 % 
FBS 
 
 
H157 
 
Buccal 
Mucosa 
Squamous cell 
carcinoma 
DMEM,  
PenStrep 10 % 
FBS 
 
KMST6          
Fibroblast 
Non-cancerous 
embryonic 
fibroblast  
DMEM, 
PenStrep 10 % 
FBS 
HeLa 
 
Cervix Cervical 
adenocarcinoma 
DMEM, 
PenStrep 10 % 
FBS 
HT29 
 
Colon  Colorectal 
adenocarcinoma 
DMEM, 
PenStrep 10 % 
FBS 
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3.2.2 Start up of Cell Culture from frozen Cells 
The frozen cryovials were held under 25 ºC running tap water for about one 
minute until defrosted. The vial was wiped down with 70 % ethanol and placed in 
a lamina flow hood where the vial contents were emptied into a 15 mL tube to 
which 5 mL of pre-warmed complete medium  was added (table 3.1). The tube 
was then centrifuged for 5 minutes at 2039 x g using a Sorvall H4000 TC6 
centrifuge (American Instrument Exchange, Inc). The supernatant was removed 
and discarded. The pellet was re-supended in fresh culture medium  and the 
suspension transferred to a 25 cm2 flask (T25). The flask was then incubated in 
humidified incubator at 37 ºC with 5 % CO2 for 24 hours after which the medium  
was checked for contamination visually, this would be indicated by cloudy 
medium . After additional 24 hours of culturing, the flask was viewed under a 
Nikon TMS microscope at a magnification of 200 X to check if the cells had 
adhered to the flask. The medium was removed and replaced with fresh culture 
medium to remove any traces of DMSO left over from the cryopreservation 
medium. 
 
3.2.3 Maintaining the cell lines 
A schedule of cell culture maintenance was conducted as follows; medium was 
visually examined for contamination daily and flasks were examined under a 
microscope for culture confluence. When contamination was not observed and 
the confluency was below 50 %, old medium was replaced with fresh complete 
growth medium.  At a confluency of 80 %, the cells were sub cultivating.  
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3.2.4 Subcultivation 
3.2.4.1 Adherent cultures 
To sub-cultivate (passage) the cultures, old medium was aspirated with a sterile 
Pasteur pipette and discarded. The culture was then washed with 3 mL 1X 
Phosphate Buffered Saline (PBS) (table 3) pre-warmed at 37 ºC. The flask was 
swirled for 15 seconds after which the PBS was aspirated with a Pasteur pipette 
and 1 mL of 1.25 % trypsin (table 3) was added to the culture. The flask was 
swirled to spread the trypsin evenly. The flask was then placed in an incubator at 
37 ºC for 2 minutes after which the culture was viewed under a microscope to 
check for detachment of the cells. When the cells were detached, 5 mL of fresh 
complete growth medium was added to deactivate the trypsin. The suspended 
cells were collected by centrifugation at 2039 x g to be used for RNA extraction. 
 
3.2.4.2 Suspension cultures 
To maintain the suspension cultures, medium was aspirated into a 15 mL tube 
which was then centrifuged for 5 minutes at 2000 x g. The supernatant was 
removed and discarded and the pellet re-supended in fresh culture medium and 
the suspension transferred to a 25 cm2 flask (T25). The flask was then incubated 
in a humidified incubator at 37 ºC with 5 % CO2 for 24 hours after which the 
medium was checked for contamination visually. To harvest the non-adherent 
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culture for RNA extraction, the pellet would be re-suspended in PBS instead of 
culture medium. 
3.3 miRNA extraction 
Extraction of miRNA proved to be difficult in the study. Thus, a method to 
extract total RNA and synthesize miRNA cDNA using specific miRNA primers 
was devised. 
 
3.3.1. Extraction of total RNA 
The procedure for the extraction of miRNA was followed for both adherent and 
suspension cultures and was performed according to the manufacturers 
instructions (Macherey-Nagel NucleoSpin®). For the RNA extraction, the 
confluent cell lines were harvested as per section 3.2.2, at a concentration of 106 
cells/mL. The cells were transferred to an Eppendorf tube and centrifuged at 2000 
× g for 5 minutes at 4 °C. Thereafter, the supernatant was removed carefully 
avoiding disturbance of the pellet formed. The cells in the pellet were then lysed 
by adding 350 μL of lysis buffer RA1 containing 3.5 μL of a β-mercaptoethanol 
solution. The pellet was homogenised by vortexing vigorously for 10 seconds. 
The lysate was then transferred to a Nucleospin® Filter which was placed in a 2 
mL collection tube. This was centrifuged for 1 minute at 11,000 x g using an 
Eppendorf 5417R bench top centrifuge. After centrifugation, the NucleoSpin® 
Filter was discarded and the RNA binding conditions of the lysate in the 
collection tube were adjusted with 350 µL 70 % ethanol. The solution was mixed 
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by pipetting up and down five times. The lysate was then pipetted onto a 
NucleoSpin® RNA Filter Column placed in a collection tube. This was then 
centrifuged for 30 seconds at 11, 000 x g. The column was transferred into a new 
2 mL collection tube. The silica membrane of the column was desalted by adding 
350 µL desalting buffer (MDB) to the column centrifuging for 1 minute at 11, 
000 x g. The collection tube was discarded and the column placed in a clean tube.  
DNA present in the column was digested with 95µL of DNase (table 3). The 
column was kept at room temperature for 15 minutes and then washed with 
200µL RA2 solution centrifuging at 11, 000 x g for 30 seconds. The flow-through 
was discarded and the column was placed back into the collection tube. A second 
and third wash were performed with 600 µL and 250 µL of RA3 solution 
respectively centrifuging at 11,000 x g for both washes. The collection tube was 
discarded and the column place in a new sterile tube into which RNA was eluted 
with 60 µL RNase free water. The concentration and quality of RNA was 
assessed using the Nanodrop ND-1000 spectrometer (ThermoScientific) and all 
the RNA samples were stored at -20 ºC. 
 
 
3.4 Reverse transcription of miRNA to cDNA using stemloop 
sequence specific primers 
Primers for the 5 miRNAs were designed by Khan, 2015 using the cotton estate 
Database available at http://www.leonxie.com/miRNAprimerDesigner.php 
The cDNA was synthesized using the Transcriptor First Strand cDNA synthesis 
kit from Roche Life Sciences, according to the manufacturer’s instructions. All 
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the reagents were kept on ice. The template RNA mixture was prepared with the 
reagents as shown in table 3.2 in a sterile, nuclease-free, thin walled PCR tube to 
a final volume of 13 μL. The tube was then incubated at 65 ºC for 10 minutes, 
after which the cDNA synthesis reagents in table 3.3 were added to make a final 
volume of 20 µL. 
 
 
Table 3.2: Reagents for template RNA mix. 
Reagent Final concentration 
RNA 
 
1µg 
Cocktail of stemloop 
sequence specific primers 
2.5µM  
 
PCR grade water 
To make 13µL 
 
 
As total RNA was extracted instead of miRNA, a cocktail of stemloop sequence 
specific primers was prepared to be used in cDNA synthesis. The cocktail was 
made by pipetting 1 µL of the reverse of each of the 5 primers into a nuclease-
free, thin walled PCR tube. The concentration of each primer was 2.5 µM.  
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Table 3.3: Reagents for cDNA synthesis  
Component Volume Final 
Concentration 
Transcriptor 
Reverse 
Transcriptase 
Reaction Buffer 
4 µL 1x 
(8mM MgCl2) 
Protector 
RNase Inhibitor 
0.5 µL 20U 
Deoxynucleotide 
Mix 
2 µL 1 mM 
Transcriptor 
Reverse 
Transcriptase 
0.5 µL 10U 
Final volume 20 µL  
 
 
The reaction was incubated at 55 °C for 30 min followed by a final inactivation 
step of 5 min incubated at 85 °C. The concentration of the synthesised cDNA was 
determined with a Nanodrop ND1000 Spectrophotometer. 
 
3.5 Analysis of gene expression profiles of the miRNAs in cancer 
and control cell lines using qRT-PCR 
Expression profiles of the five miRNAs were analysed via quantitative real-time 
PCR (qRT-PCR). The housekeeping miRNA miR-191a as well as the house 
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keeping gene GAPDH, were used as references. All reactions were performed on 
the LightCycler® 480 System (Roche Applied Science) instrument. The reactions 
were prepared as outlined in table 3.4. 
 
        Table 3.4: Reagents for a standard qRT-PCR reaction 
Reagents Final Concentration 
SYBR Green Master 
Mix (10X) 
1X 
Forward Primer  1 µM 
Reverse Primer 1 µM 
cDNA 250ng 
PCR Grade dH2O Variable to make 
20µL 
Final Volume 20 µL 
 
 
A polymerase chain reacction was performed on each of the 5 miRNAs in each 
cell line. In addition, reactions for the reference miRNA primer 191a, reference 
housekeeping gene primer GAPDH and a no-template control (water) were also 
set up for each cell line. An aliquot of reaction mastermix was pipetted into each 
well of a 96 well plate and an aliquot of cDNA from each cancer cell line was 
then added as the PCR template to each well respectively. The experiment was set 
up with decreasing cDNA concentrations starting with 250 ng of cDNA to 0.0025 
ng.  Thus, 250 ng of cDNA for each cell line was run in duplicate for each primer 
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in order to construct a standard curve. A negative control was set up for each run 
containing 1 μL of PCR-grade water as a substitute for cDNA. The 96 well plates 
were sealed with clear sealing film and a qRT-PCR run set up on the 
LightCycler® 480 instrument according to the parameters in table 3.5. The 
evaluating parameters selected for data analysis were fluorescence (d[F1]/dT), 
melting temperature (Tm) and crossing point (Cp). The Second Derivative 
Maximum algorithm was employed for Cp determination where Cp was 
measured at the maximum increase of fluorescence.  
 
Specificity of real-time PCR primers was determined by amplification plots, 
melting temperature, and melting curve analysis using LightCycler Software, 
Version 1.5 (Roche Diagnostics). Standard curves were generated using a dilution 
series in the concentration range 250ng to 0.0025 ng. The PCR efficiencies were 
calculated using the REST® software and all threshold cycle (Ct) values were 
taken into consideration according to the following equation: E=10[-1/slope] 
(Pfaffl 2002). 
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Table 3.5: Cycling Protocol for the qRT-PCR  
Detection Format Block Type Reaction volume 
SYBR® Green  96 well 20µL 
Programme Name Cycles Analysis Mode 
Pre-incubation 1 None 
Amplification 40 Quantification 
Melting Curve 1 Melting Curve 
Cooling 1 None 
Programme Name Target (ºC) Acquisition  
Mode 
Hold 
(hh:mm:ss) 
Pre-incubation 95 None 00:03:00 
 
 
 
 
Amplification 
95 None 00:00:10 
 
Primer Dependent 
(65ºC) 
None 00:00:20 
 
72 Single 00:00:10 
 
 
 
Melting curve 
95 None 00:00:05 
 
65 None 00:01:00 
 
97 Continuous 5-10 
acquisitions/ºC 
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Cooling 40 None 00:00:10 
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3.6 Results and Discussion 
 
This chapter aimed to investigate the utility of a panel of miRNAs (miR1, miR2, 
miR3, miR4 and miR5) predicted (in silico) to be dys-regulated in prostate cancer 
as potential diagnostic biomarkers. The main objective was to evaluate the 
expression of these miRNAs in a prostate cancer cell line, non-cancerous prostate 
cell line, benign prostate hyperplasia as well as a diverse cohort of other cell lines 
(table 3.1) 
 
3.6.1 Normalisation and Statistical Analysis 
The accuracy of qRT-PCR is heavily dependent on the proper normalization of 
expression data. There are several variables in a qRT-PCR experiment that need 
to be controlled for, both technical as well as biological variables. Technical 
variables include differences in sample collection, RNA extraction and target 
quantification and biological variables can be sample-to-sample inconsistency 
(Deo et al., 2011). Therefore, normalization is performed with the purpose to 
remove experimentally induced variation and to differentiate true biological 
changes. An inappropriate normalization of qRT-PCR data can lead to misleading 
conclusions (Peltier and Latham, 2008, Roberts et al, 2014). Thus, the choice of 
normalization method is a crucial step in data analysis.  
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miRNAs pose a significant challenge for normalization (Deo et al., 2011). This is 
thought to be due to the fact that miRNAs only represent 0.01 % of  total RNA. 
Although this is a small fraction, it could have significant variation across 
different samples (Peltier and Latham, 2008). Despite these challenges, there are 
three normalization strategies which aid in expression profiling of miRNAs which 
include (i) average of all the quantification cycles values (Cq) from the 
experiments, (ii) stably expressed endogenous reference miRNAs, and (iii) 
external spike-in synthetic oligonucleotides. In this study, miR-191a (Schaefer et 
al, 2010; Deo et al, 2011), and GADPH (Ji et al, 2013) were used as reference 
nucleic acids for normalization, as they have been identified  to be stably 
expressed in prostate tissue.  
 
3.6.2 Standardization of qRT-PCR results 
The miRNA expression studies were quantified using the Pfaffl model. This 
method requires the use of the Relative Expression Software Tool (REST®), a 
freely available Excel® based application that compares a sample group to a 
control group and calculates the relative expression between them (Pfaffl, 2004). 
REST® uses a mathematical model (Pfaffl et al., 2002) that is dependent on the 
mean crossing point deviation between a sample and a control which are 
normalized by the mean crossing point deviation of a reference gene, in this case, 
a housekeeping miRNA. 
The mathematical model in REST® relies on the determination of the crossing 
points (figure 3.1). The crossing point (Cp) or the threshold cycle (Ct) is the cycle 
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at which fluorescence achieves a defined threshold. It corresponds to the cycle at 
which a statistically significant increase in fluorescence is first detected in a qRT-
PCR reaction (Heid et al., 1996; Rodriguez-Lazaro and Hernandez, 2013). This 
concept is the basis for accurate and reproducible quantification using qRT-PCR 
(Rodriguez-Lazaro and Hernandez, 2013). This is because a sample’s Cp value 
depends on the initial concentration of DNA in the sample. A sample with a 
lower initial concentration of target DNA requires more amplification cycles to 
reach the Cp value. A sample with higher concentration requires fewer cycles. 
Thus, Cp values can be used as a quantitative measure of the input target number 
(Heid et al., 1996).  
 
 
Figure 3.1: Amplification curve showing the crossing points at 19 cycles for one 
duplicate run and 21 cycles for another duplicate run. The amplification curve 
also shows reproducibility between replicates. 
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The REST® software aids in relative quantification analysis of qRT-PCR results. 
However, relative quantification is dependent on PCR efficiency (Pfaffl et al., 
2002). The slope of the standard curve describes the kinetics of the PCR 
amplification. It indicates how quickly the amount of target nucleic acid (NA) can 
be expected to increase with the amplification cycles (Livak et al., 1997). The 
slope of the standard curve is also referred to as the efficiency of the 
amplification reaction. A perfect amplification reaction would produce a standard 
curve with an efficiency of 2, because the amount of target NA would double 
with each amplification cycle (Pfaffl et al., 2004). The PCR efficiency can easily 
be calculated using the formula: 
 
E = 10 -1/slope 
 
Equation 3.1:  Efficiency of PCR is dependent on the gradient which describes 
the kinetics of the reaction.  (Pfaffl et al., 2004). 
 
An ideal slope would be -3.3 to give an efficiency of 2. However, a range of 3.2 
to 3.6 is acceptable as the gradient (Livak et al., 1997; Pfaffl et al., 2004;Ruijter 
et al., 2009). Thus, a standard curve is a requirement in both relative and absolute 
quantification. 
 
A relative quantification analysis was performed on the samples in this study. The 
expression levels of five miRNAs were evaluated in 11 cell line samples (table 
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3.1). A relative quantification analysis compares two ratios, the ratio of a target 
nucleic acid (NA) sequence to a reference NA sequence in an unknown sample 
and the ratio of the same two sequences in a standard sample, the calibrator 
(miR191a). This target sequence is the nucleic acid of interest, while the 
reference is a nucleic acid that is found at constant copy number in all samples 
and serves as endogenous control. The reference is used for normalization of 
sample-to-sample differences. The calibrator is typically a positive sample with a 
stable ratio of target-to- reference and is used to normalize all samples within one 
run (Roberts et al, 2014). Equation 3.2 shows how the result of this relationship is 
expressed.  
 
 
 
 
Equation 3.2: Normalization ratio for relative quantification analysis. (Pfaffl et 
al., 2004). 
 
3.6.3 Importance of Melting Peak Analysis in qRT-PCR 
The temperature at which a DNA strand separates or melts when heated can vary 
over a wide range, depending on the sequence, the length of the strand, and the 
GC content of the strand. For example, melting temperatures can vary for 
products of the same length but different GC/AT ratio, or for products with the 
                                     conc. Target                               conc. target 
                                    conc. reference   sample        :          conc. reference     Calibrator 
Normalized Ratio =     
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same length and GC content, but with a different GC distribution. Thus, a melting 
peak analysis can be performed to determine the characteristic melting 
temperature of the target DNA and to identify products based on their melting 
temperature (Tm). This distinguishes target amplicons from PCR artefacts such as 
primer dimers (Fraga et al., 2008).  The KAPA SYBR FAST qRT-PCR kit 
optimized for LightCycler® 480 uses SYBR® Green I dye chemistry to detect 
the accumulation of an amplicon. SYBR® Green is a fluorogenic intercalating 
dye that emits a strong fluorescent signal upon binding to double-stranded DNA. 
In its unbound form, fluorescence is diminished (Nestorov et al., 2013).   
 
3.6.4 Analysis and Quantification of qRT-PCR data  
3.6.4.1 Analysis of qRT-PCR normalisation  
Normalisation of qRT-PCR is important because of the many variables that need 
to be controlled for. Figure 3.2 shows the comparison of miR1 expression in 
KMST-6 and A549 before normalization with the housekeeping miRNA, 
miR191. The miRNA is down-regulated in both instances. However, the factor by 
which the miRNA is down-regulated is 8.626 before normalisation and 15.66 
after normalization. The p-values are 0.0895 and 0.0435 respectively. 
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Figure 3.2: Comparison of miR1 expression between the KMST-6 cell line and A459 cell line, before the normalization test (green 
writing) and after performing normalization (in blue). 
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3.6.4.2 Analysis of amplification curves 
Figure 3.3 shows the amplification curves of miR1 in KMST. The figure shows 
reproducibility of the duplicate runs.  
 
Figure 3.3: Amplification curve of miR1 in the KMST cell line. The different 
amplification curves represent different concentrations of KMST cDNA from 250 
ng to 0.0025 ng in duplicate from left to right.  
 
Examining figure 3.3, it can be seen that the reproducibility in the 250 ng 
duplicates was not consistent. This could have been caused by a number of 
reasons. One could be the introduction of random errors; this is indicated by the 
observation that one duplicate has a higher Cp value than the other duplicate. This 
could have resulted from adding more cDNA to the first duplicate hence 
demonstrating the importance of sample normalization as well as robust statistical 
analyses so that the results reflect an accurate biological event within each cell 
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line. Comparing the amplification curves of figure 3.3 and 3.4, it can be observed 
that the latter shows better evidence of varying cDNA concentration than the 
former.  
 
 
Figure 3.4: Amplification curve of miR1 in BPH1 cells. The different 
amplification curves represent different concentrations of BPH1 cDNA from 250 
ng to 0.0025 ng in duplicate from left to right.  
 
3.6.4.3 qRT-PCR melting peak analysis  
A melting curve analysis is important to determine the homogeneity of the PCR 
product of concern. Figure 3.5 shows the melting peak of miR1 in BPH1 cells. A 
prominent peak is seen at the Tm of 83 ºC. This corresponds to the expected Tm of 
miR1 which was calculated from the miRNA sequence obtained from mirBase. 
Figure 3.6 shows the melting peak of the housekeeping miRNA in the BPH1 cell 
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line. Examining figure 3.5 shows that there are 3 more additional peaks at 67 ºC, 
79 ºC and 91 ºC in addition to the expected peak at 83 ºC.  
One explanation of this is that DNA melting curves depend on the G/C content of 
a DNA strand (Rodriguez-Lazaro and Hernandez, 2013). As the dsDNA starts to 
melt, regions of the amplicon that are more stable (i.e G/C rich) do not melt 
immediately (Draghici et al., 2008; Rodriguez-Lazaro and Hernandez, 2013). 
These stable regions maintain their dsDNA configuration until the temperature is 
sufficiently high to cause it to melt. This scenario results in 2 melting phases 
(Draghici et al., 2008; Nestorov et al., 2013; Rodriguez-Lazaro and Hernandez, 
2013). The data in figure 3.5 is consistent with this interpretation. Additional 
sequence factors can also cause products to melt in multiple phases. These 
include amplicon misalignment in A/T rich regions, and designs that have 
secondary structure in the amplicon region (Rodriguez-Lazaro and Hernandez, 
2013).  Melting curves for the rest of the miRNAs in the various cell lines can be 
found in appendix B. 
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Figure 3.5: Melting peak of miR1 in BPH1 cells. A prominent peak is seen at the 
Tm of 83 ºC. 
 
 
Figure 3.6: Melting peak of miR191 in BPH1 cells. A prominent peak is seen at 
the Tm of 84 ºC. 
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3.6.4.4 Analysis of qRT-PCR Gene Expression data 
An analysis was done to evaluate the specificity of the putative miRNA as 
prostate cancer biomarkers. This was done by analysing their expression patterns 
in benign prostate hyperplasia, BPH1, LNCaP, PNT1a as well as in a panel of six 
different cancer cell lines (refer to table 3.1). The KMST cell line, a normal skin 
fibroblast was used for sample normalisation.  
The REST® software calculates relative expression between two samples using a 
statistical model called the Pair Wise Fixed Reallocation Randomization Test to 
normalise data. The data obtained were imported into an Excel® spreadsheet to 
create a graph showing the relative expression levels of miR1. miR2, miR3, miR4 
and miR5 in the various cancer cell lines. This expression was relative to the 
expression levels of the miRNAs in the control samples, where the control 
samples were given an arbitrary value of one which indicates no variation of 
regulation of the miRNAs of interest.  
 
Differential expression of the 5 miRNAs was observed across all cancer cell lines 
(figure 3.7), with miR2, miR3 and miR5 being significantly highly differentially 
expressed in the prostate cancer cell line LNCaP when compared to the other 
cancer cell lines. The expression ratios were 8.79, 13.87 and 15.32 respectively 
(Table 3.6). Thus, these miRNAs have the highest potential to be biomarkers for 
prostate cancer.  Also observed, was the expression of miR1 in the benign 
prostate hyperplasia cell line (BPH1). The miRNA is significantly highly 
expressed in BPH1 when compared to other cancer cell lines, (figure 3.4), with an 
expression ratio of 4.85 (table 3.6).  Currently, there are no molecular markers 
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identified for clinical use for detection of benign prostate hyperplasia or its 
likelihood to progress to cancer (Cannon and Getzenberg, 2012; Kunar et al., 
2013).  
DIANA-Tarbase generated pathways indicated that miR1 may be involved in 
various cancer causing related pathways including regulation of actin 
cytoskeleton and glucosaminoglycan biosynthesis (figure 2.6). Studies have 
shown that genes involved in actin cytoskeleton regulation, calcium signalling 
and glucosaminoglycan biosynthesis are targeted in BPH (Savli et al., 2008; Endo 
et al., 2009). Thus, this could explain the predicted association of miR1 in these 
pathways. However, more studies would have to be conducted on miR1 to 
determine its potential as a good candidate for benign prostate hyperplasia. 
Examining miR2, it was observed that it was significantly highly expressed in 
LNCaP when compared to the other cell lines. Expression of miR2 was down-
regulated in BPH1, A459, HEPG2, HeLa and H157 by ratios of -2.4, -4.0, -4.10, -
7.82 and -4.28 respectively (table 3.6). The miRNA was up-regulated in MCF7 
by a ratio of 0.85 in HT29 by 1.09 and in LNCaP by 8.79. Thus, miR2 is could be 
considered as a possible good indicator of prostate cancer. From DAVID, miR2 
was predicted to target the gene AFAP1 (Table 2.5). This gene is known to 
encode a protein that is a potential modulator of actin filament integrity which 
responds to cellular signals (Garzon et al., 2014). This gene is not well 
characterized in literature. However, further prediction studies in STRING 
indicated that the gene is involved in protein cancer networks and it is linked to 
another gene CTNND1 which is regulated by miR4.  
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GeneHub-GEPIS showed that AFAP1 is expressed in both normal and tumour 
prostate tissues (figure 2.16). However, the expression of this gene in the tumour 
tissue was shown to be down-regulated. This could be as a result of the action of 
over-expression of miR2. Further studies would have to be undertaken to validate 
this. 
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Figure 3.7: Relative expression ratio plot of the five miRNAs in various cancer cell lines including prostate cancer (LNCaP) and 
benign prostate hyperplasia (BPH1). The bars indicate up-regulation (above 0) of the miRNAs and down-regulation (below 0) of 
the miRNA. 
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Table 3.6: Fold expression ratios of the five miRNAs 
 BPH1 LNCaP A549 HEPG2 MCF7 HeLa HT29 H157 
miR1 4.85 -0.49 -3.96 -4.32 0.82 -3.94 -1.40 0.6 
miR2 -2.4 8.79 -4.0 -4.10 0.85 -7.82 1.13 -4.38 
miR3 -6.51 13.87 0.3 0.34 -0.69 -4.38 -1.04 0.11 
miR4 1.99 1.92 -6.99 -1.2 0.50 -4.01 1.11 -4.79 
miR5 -5.61 15.34 -2.69 7.057 0.79 -4.00 3.59 3.59 
GAPDH -8.560 1.189 -8.92 2.78 6.91 2.58 -1.01 2.58 
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An examination of the expression of miR3 shows that it is significantly over-
expressed by a ratio of 13.87 in the prostate cancer cell line LNCaP (table 3.6). 
Table 3.6 also shows that miR3 is under-expressed in BPH1 by a ratio of -6.51. 
Comparing the expression ratios of miR3 in BPH1 and LNCaP indicates that it 
could serve as a good indicator of prostate cancer. The under-expression of miR3 
in BPH1 could help in the specificity of prostate cancer diagnosis. This is because 
the current most widely used biomarker PSA cannot specifically distinguish 
between benign prostate hyperplasia and prostate cancer (Velonas et al., 2013; 
Qu et al., 2014). PSA is organ-specific and not disease-specific. Thus, it is prone 
to high false-positive diagnosis (Heidenreich et al., 2011; Velonas et al., 2013; 
Qu et al., 2014) as there are several reasons, in addition to prostate cancer, for 
elevated levels of PSA found in a man's blood. 
From the in silico study, miR3 was predicted to regulate two genes, MNT and 
LIG4. The MAX binding protein, (MNT) has been found to be highly expressed 
in prostate tumour tissue with a digital expression unit (DEU) of 94.6 (figure 2.8). 
However, the gene LIG4 is not expressed in prostate tumours. The qRT-PCR 
analysis showed that miR5 was the most over expressed miRNA with an 
expression ratio of 15.32 in LNCaP (table 3.6). It was not highly expressed in 
BPH1, A549 and HeLa with expression ratios of -5.61, -2.6 and -4.0 respectively. 
It was significantly highly expressed in HEPG2 with an expression ratio of 7.057. 
Expression levels in H157, HT29 and MCF7 were 3.59, 1.61 and 0.50 
respectively. Thus, it could be a good indicator of prostate cancer. However, its 
level of expression in HEPG2 (liver cancer) takes away from its specificity to 
prostate cancer. The miRNA was predicted to be involved in the regulation of the 
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genes YWHAZ and TNFSF13B (table 2.5). Several studies have demonstrated 
that YWHAZ has a pivotal role in tumour cell proliferation through its over-
expression (Chen et al., 2012; Nishimura et al., 2013). In many cancers, 
TNFSF13B has been shown to be an endogenous inhibitor of neovascularisation. 
This is a critical component of the negative control mechanism that operates in 
normal cells but is missing in tumour cells (Vassiliki et al., 2008; Deng et al., 
2012). 
 
3.6.5 Summary and conclusion 
The validation of biomarkers is a critical step in the biomarker discovery pipeline. 
In order to become a clinically approved marker, a potential biomarker should be 
confirmed and validated using hundreds of specimens. The tests should also be 
reproducible, specific and sensitive (Drucker and Krapfenbauer, 2013). 
Microarray technologies have previously been used to identify differentially 
expressed genes and have been used in numerous studies pertaining to human 
malignancies. However, microarray results have been influenced by various 
sources of variability including minor changes in experimental conditions such as 
biological heterogeneity in the population as well as in the specimen, specimen 
collection and handling and RNA extraction and amplification (Murphy, 2002; 
Abdulla-Sayani et al., 2006; Draghici et al., 2008). This would make it difficult to 
reproduce the results. As a consequence, differentially expressed genes in such 
preliminary discoveries could be confirmed using alternative methods such as 
qRT-PCR (Hu et al., 2006).  Quantitative real time PCR quantifies small changes 
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in gene expression and thus can give insight into the role of a gene and/or its 
product. These changes in gene expression can be indicative of a diseased state as 
the body tries to maintain homeostasis (Pfaffl, 2001). 
 
In this study, we evaluated the expression profiles of five miRNAs that were 
predicted via in silico methods to play regulatory roles in cancer onset and 
progression. Examination of the expression of these miRNAs in a panel of cancer 
cell lines showed that miR1 is over-expressed in BPH1. Thus it has the potential 
to serve as an indicator of benign prostate hyperplasia. However, because of its 
expression in MCF7 and H157 albeit minutely (0.8 and 0.6 respectively); it may 
have to be used in conjunction with other biomarkers or processes. It was also 
clear that miR3 was over-expressed in LNCaP and not in any other cell line. The 
expression ratio of miR3 in LNCaP was found to be 13.87. This makes it a good 
biomarker candidate for prostate cancer diagnosis. The study also showed that 
miR2 could be another potential biomarker for prostate cancer diagnosis. It had 
an expression ratio of 8.79 in LNCaP. However, it is also expressed in two other 
cancer cell lines HT29 and MCF7 with expression ratios of 1.09 and 0.85 
respectively. However, one miRNA may not be sufficient for the detection of a 
condition (Carlsson et al., 2011). Thus, both miRNAs could be used in 
combination with other biomarkers. Additionally, more cell lines and patient 
samples would need to be evaluated to establish the specificity of the expression 
of these miRNAs in BPH1 and prostate cancer. The use of a singular miRNA, or 
a combination of miRNAs could potentially improve the predictive accuracy or 
prognostics as well as treatment outcomes in prostate cancer (PCa). The use of 
these markers could play an important role in screening for PCa. This is because 
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current methods are invasive, and painful. Identifying biomolecules that can be 
present in bodily samples like urine could reduce unnecessary biopsies. 
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Chapter 4 
4.1 General discussion and future work 
Prostate cancer (PCa) is the most frequent tumour in men and a major cause of 
cancer-related morbidity and mortality (WHO, 2015). According to the 
International Agency for Research on Cancer (GLOBOCAN) in 2012, prostate 
cancer was among the most commonly diagnosed cancers in males, coming 
second after lung cancer. Additionally, prostate cancer makes up 8% of all 
cancers diagnosed in the world. In 2013, 238,590 men were diagnosed with 
cancer of the prostate and 29,720 men died as a result. Approximately 4500 of the 
deaths related to PCa were in South Africa (Cancer Association of South Africa, 
2014) which makes PCa a global epidemic. Current diagnostic tools include 
digital rectal examinations (DRE) (Schröder et al., 1998), prostate specific 
antigen test (PSA) (Lu-Yao et al., 2003), biopsy (Essink-Bot et al., 1998) and 
ultra sound (Bonekamp et al., 2011). All these diagnostic methods currently being 
employed are however, invasive, lack specificity and sensitivity (ACS, 2014; 
Djulbegovic et al., 2010). Additionally, the diagnostic application of the prostate 
specific antigen (PSA) has led to widespread over-diagnosis and subsequent 
overtreatment of clinically insignificant tumours (Simmons et al., 2011; Stavridis 
et al., 2010; Wolf et al., 2010).  It is foreseen that this problem may increase in 
the future (Bitu, 2015; Siegel, 2015). Therefore, there is a need for a less invasive 
early detection method with the ability to overcome the lack of specificity and 
sensitivity. Biomarkers have recently been identified as a viable option for early 
detection of disease for example biological indicators i.e. DNA, RNA, proteins 
and microRNAs (miRNA). 
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Mature miRNAs are a class of naturally occurring, small non-coding RNA 
molecules. They are partially complementary to one or more messenger RNA 
(mRNA) molecules, and their main function is to down-regulate protein 
expression in a variety of manners, including translational repression, mRNA 
cleavage,  and de-adenylation (Filipowicz, 2005; He et al., 2005; Mraz et al., 
2009). miRNAs are becoming increasingly recognized as powerful biomarkers 
for human disease. The information potential held by miRNAs, combined with 
the fact that they are stable in serum and plasma, has led to a rapidly growing 
interest in using miRNAs in blood or urine as diagnostic and prognostic 
biomarkers (He et al., 2005). The aim of this study was therefore to identify and 
characterize miRNAs, as a class of less invasive biomarkers for early diagnosis of 
prostate cancer. 
A number of miRNAs have been shown to influence key cellular processes 
involved in prostate tumourigenesis, including negative regulation of apoptosis, 
cell proliferation and migration and the androgen signalling pathway (Carlsson et 
al., 2011). Currently, a few studies have been undertaken to identify miRNA 
specific for prostate cancer Ambs et al., 2008 suggested that miRNA expression 
alters the development and progression of prostate cancer and some of the cancer-
related genes are regulated by miRNAs (Ambs et al., 2008). Porkka et al., also 
identified 51 miRNAs that are differentially expressed between benign and 
malignant prostate tumours, of which 37 were down-regulated and 14 up-
regulated (Porkka et al., 2007). These differentially expressed miRNAs lead to 
alteration in the expression and activity of their targets in prostate cancer. MiR-21 
in prostate cancer has been shown to stimulate androgen-dependent cell growth 
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and can also rescue cells from androgen deficient growth arrest. This indicated 
that miR-21 may also mediate castrate-resistant prostate cancer (CRPC) 
development (Jackson et al., 2014). Several studies, (Li et al., 2012; Brase et al., 
2011; Jackson et al., 2014) recently established that tissue miR-21 expression 
levels may have clinical importance. They evaluated miR-21 expression levels in 
a cohort of 169 radical prostatectomy tissue samples and found that increase in 
miR-21 expression levels was associated with pathological stage of prostate 
cancer. They went on to demonstrate in vivo tumour growth repression in a mouse 
model treated with a miR-21 inhibitor. 
 
Brase et al., 2011 also examined miR-141 as an miRNA correlated with tumour 
progression in cancer. The study identified it as one of the miRNAs present at 
high levels in patients with malignant tumours.  In the same study, MiR-141 was 
also shown to distinguish between patients with metastatic prostate cancer and 
healthy controls. However, both miR21 and miR141 are implicated in other 
cancers apart from prostate cancer and thus may not be suitable diagnostic 
markers for the disease but rather have prognostic value, (Li et al., 2012; Brase et 
al., 2011; Jackson et al., 2014). Thus, the need to identify putative novel miRNAs 
is still a necessity. 
 
The study investigated a panel of five miRNAs implicated in prostate cancer as 
putative biomarkers for detection of the disease. The panel was mined from 
online databases and literature mining in a previous study (Khan, 2015). It is well 
known that miRNAs control the expression of genes involved in various 
biological processes (Bartel, 2009). This is done by binding to the 3’ UTR of their 
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target mRNA (section 1.6). Thus, target gene prediction of miRNA is important 
in identifying which genes are affected by miRNA dys-regulation in diseases 
including prostate cancer.  
 
Target prediction of miRNA target genes was done using TargetScanHuman and 
miRDB. These are platforms that are publicly available. The target genes 
identified for the five miRNAs via TargetScanHuman were 1502. miRDB 
predicted 1076 target genes for the miRNAs. It was interesting to see a 28 % 
difference in the results from the two databases. This could be attributed to the 
properties of the two databases. The combined list from miRDB and 
TargetScanHuman were used as input into DAVID. This tool allows for 
functional annotation of genes. Thus, the processes that the genes are involved 
such as cellular component, biological function and molecular function are 
discerned.  
 
The list of genes in DAVID were reduced by looking at the enrichment score. An 
enrichment score greater than 1.3 was considered significant. The enrichment 
score is a figure of how important the particular gene is in the submitted gene list. 
Literature mining of the genes was also performed. Those genes involved in PCa 
but not experimentally validated were prioritized.  
 
It was found that terms such as regulation of apoptosis (figure 2.3) in biological 
processes are crucial to cancer onset. In the same way, genes with molecular 
functions such as metal ion binding and nucleoside binding were prioritized 
 
 
 
 
131 
 
(figure 2.4). As were genes with their cellular components localised to the cell 
surface (figure 2.2). Table 2.5 summarizes the miRNAs and the genes they target. 
Analysis of gene interaction networks in STRING showed that the genes are 
involved in protein networks with each other as well as with  genes such as RAF1 
which is a proto-oncogene (Mikula et al., 2001) and CASP3 which is responsible 
for apoptosis execution (Jin et al ., 2007). DIANA-Tarbase generated a heat map 
that indicated the involvement of the five miRNAs in cancer causing pathways, 
such as transcription mis-regulation in cancer as well as lipid metabolism. The 
miRNAs involved in these pathways included miR1, miR3 and miR5. 
 
Even though in silico methods are a cost effective, easy way of identifying novel 
biomarkers and maybe a tool of choice by many scientists, they generate a 
plethora of data that should be analysed critically. It is also important to validate 
in silico results. Thus, a molecular approach was employed to compare 
expression of the 5 miRNAs predicted to be involved in gene regulation during 
prostate cancer. 
 
In this study, we evaluated the expression profiles of the five miRNAs that were 
predicted via in silico methods to play regulatory roles in prostate cancer. We 
investigated expression profiles of the five miRNAs using qRT-PCR. This was 
done in various cell lines including the PCa cell line, benign hyperplasia cell line, 
normal prostate cell line, KMST, MCF12 and a panel of 6 other cancer cell lines. 
The expression profiles of the miRNAs in the cell were analysed using the 
relative expression tool REST®.  
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A hypothesis was made that the miRNAs would be significantly highly expressed 
in LNCaP and that additionally, some of the miRNAs may also show significant 
high expression in the BPH1. It was observed, as discussed in 3.6 that miR1 was 
significantly expressed in BPH1 and miR3 was highly expressed in LNCaP. Thus 
these hold potential to be biomarkers for BPH and PCa upon further work. 
 
However, because of the expression of miR1 in MCF7 and H157 albeit minutely 
(0.8 and 0.6 respectively); It may have to be used in combination with another 
biomarker. The expression ratio of miR3 in LNCaP was found to be 13.87. This 
makes it a good biomarker for prostate cancer diagnosis. It has been reported that 
using more than one miRNA for cancer detection is more appropriate (Carlsson et 
al., 2011). Thus, additional cell lines and patient samples would need to be 
evaluated to establish the specificity of the expression of miR3 in prostate cancer. 
The study also showed that miR2 could be another potential biomarker for 
prostate cancer diagnosis. It had an expression ratio of 8.79 in LNCaP. However, 
it is also expressed in two other cancer cell lines HT29 and MCF7 with 
expression ratios of 1.09 and 0.85 respectively. Thus, it could be used in 
combination with another biomarker.  
 
The use of a singular miRNA, or a combination of miRNAs could potentially 
improve the predictive accuracy or prognostics as well as treatment outcomes in 
prostate cancer (PCa). The use of these markers could play an important role in 
screening for PCa, however the objective remains to reduce the number of 
unnecessary biopsies performed and to limit the invasive procedures performed to 
differentiate between normal cells, benign tumours and PCa. 
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There is evidence from in vitro and in vivo studies that alteration in miRNA 
function plays a role in prostate carcinogenesis (Berger et al., 2014 and Murata et 
al., 2012). miRNA dysregulation influences a number of critical cellular 
processes involved in carcinogenesis, including but not limited to: stimulation of 
the cell cycle, avoidance of apoptosis, epithelial mesenchymal transition and 
modulation of AR-mediated signalling (Ozen et al., 2008; Clape et al., 2009; Fu 
et al., 2010; Schaefer et al., 2010). 
 
Further understanding of the expression patterns of miRNA dys-regulation may 
allow the development of novel diagnostic and therapeutic strategies involving 
miRNA augmentation or inhibition in the future. The potential to detect 
circulating miRNAs in serum and potentially, in urine, clearly exists (Chen et al., 
2008; Mitchell et al., 2008; Li et al., 2007; Park et al., 2009). The present study 
revealed miRNAs that may play a role in detection of prostate cancer and have 
demonstrated over- or under-expression when comparing non- cancerous prostate 
cells to prostate cancer cells. Further investigation of these miRNAs in larger 
patient groups will help to define their potential role as diagnostic and prognostic 
biomarkers in the future.  
 Future work would include examination of the expression profiles of the 
miRNAs in a larger panel of cells as well as investigation of expression profiles 
of these miRNAs in patient samples such as blood, urine and saliva. It would also 
be interesting to analyse the UTR sequences of the miRNAs targets 
experimentally. This will prove that the target genes identified using the in silico 
methods are indeed regulated by these miRNAs. Once the target genes are 
confirmed, further analyses can be performed on the miRNAs to study their roles 
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in prostate cancer development. This can be done by performing knockdown of 
the miRNA via Locked Nucleic Acid modified probes. This will aid in a wet 
bench functional analysis of the miRNA. 
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Appendix A 
 
Chapter 2 supplementary information. 
TiGER and GeneHub-GEPIS expression profiles of the of FOXC1, TNFSF13B, 
BIRC2, CTNND1, TNFSF15 and AFAP1 genes. 
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Figure 2.11: Expression profile for FOXC1 from TiGER (A) FOXC1 is preferentially expressed in the heart with an expression 
enrichment value greater than 6. Expression in prostate tissue is between 3 and 4.  GeneHUB-GEPIS (B). Normal tissue expression is 
shown in blue; over expression in tumour tissue is shown in yellow. 
 
A 
B 
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Figure 2.12: Expression profile for TNFSF13B from TiGER (A) TNFSF13B is preferentially expressed in the thymus with an 
expression enrichment value greater than 13. Expression in prostate tissue is about 2.5. GeneHUB-GEPIS (B). Normal tissue 
expression is shown in blue; over expression in tumour tissue is shown in yellow. 
 
B 
A 
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Figure 2.13: Expression profile for BIRC2 from TiGER (A) BIRC2 is preferentially expressed in the thymus with an 
expression enrichment value greater than 4.5. Expression in prostate tissue is less than 0.5.  GeneHUB-GEPIS (B). Normal 
tissue expression is shown in blue; over expression in tumour tissue is shown in yellow. 
 
A 
B 
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Figure 2.14: Expression profile for CTNND1 from TiGER (A) CTNND1 is preferentially expressed in the bladder with an expression 
enrichment value greater than 2.5. Expression in prostate tissue is between 1 and 0.5.   GeneHUB-GEPIS (B). Normal tissue expression is 
shown in blue; over expression in tumour tissue is shown in yellow. 
 
A 
B 
 
 
 
 
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15: Expression profile for TNFSF15 from GeneHUB-GEPIS . Normal tissue expression is shown in blue; 
over expression in tumour tissue is shown in yellow. There was no expression profile available for the gene in the TiGER 
database. 
B 
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Figure 2.16: Expression profile for AFAP1 from GeneHUB-GEPIS. Normal tissue expression is shown in blue; over expression in 
tumour tissue is shown in yellow. There was no expression profile available for the gene in the TiGER database. 
 
B 
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2.  Gene list 
Table 3: Tabular representation of the 502 target genes identified using in silico 
methods. 
SGIP1 
CLHC1 SGIP1 ANP32B MSH6 
E2F5 
SAMD5 E2F5 MDM4 PPP4R4 
ADAM22 
LINC00692 TFAP2B ANXA1 ITGA4 
FOXN2 
ERO1LB TLE3 BRINP3 POGK 
TOX 
TMSB4Y PACS1 UBE2E3 PLSCR1 
KCMF1 
OR6B2 MECP2 CYP4F31P C3orf58 
GABRB1 
TWF1 FOXC1 TNKS MAPK6 
MED13 
TMSB4X KIAA1644 RP11-664D7.4 ZFP36L1 
RAD23B 
CRYM AFAP1 GEMIN2 PPARG 
YWHAZ 
ATP5SL EN1 TMEM74B PTPN4 
PCDHB16 
TMED5 TMEM63B TMEM209 FAM46A 
PRKACB 
RP11-379H8.1 ZNRF2 BCHE TSPAN13 
SLC4A10 
KRTAP20-2 PIK3R2 CTPS2 RAPGEF6 
WWTR1 
AF131215.5 DPYSL5 COX7C VAPA 
SFMBT2 
ADAM2 KMT2D SNAP25 TMX3 
NIPSNAP3A 
C19orf59 HCFC1 KERA VEZF1 
C18orf25 
OR2C3 MYRF MMP21 HIC2 
CSNK1G3 
CTD-3148I10.1 SLC6A17 PSMD4 CLOCK 
ENOX2 
FAM60A BSN DCDC2B SH3KBP1 
KLRC4 
SLC39A6 ITGA3 RBM22 CLDN18 
CHD1 
ATP6AP2 MBD6 OR13J1 CSNK1G3 
CHCHD3 
RSPH4A CES4A C7orf71 NEDD1 
ZNF236 
SRFBP1 SHANK2 WDR83 GOLPH3 
HNRNPA0 
PLK2 CADM4 VIMP ADORA2B 
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XPO1 
RGS4 SZRD1 NDUFC1 SLAIN2 
RANBP9 
B3GNT2 TMEM222 ZNF572 TMED7 
MEX3C 
GPATCH2L PRKACA MCOLN3 STXBP4 
FAM120A 
ACTR6 CNIH2 HTR7 ZBTB44 
NWD2 
AL353698.1 TMEM151A HSD3B1 NUP98 
GANAB 
MTRNR2L8 DYSF EIF4ENIF1 SLC31A2 
EPHA5 
RNF146 TCP11L1 DNTT CAT 
AKIRIN2 
FAM24A MINK1 ZNF460 UQCRH 
CYTIP 
GNA14 MOCS3 CLDN12 SLC31A2 
KIAA2022 
NOTCH2NL STAC2 NXPH1 TPD52 
MAT2B 
FAM216B CNTNAP1 PTS MBD1 
PPP2R3A 
PPM1K XYLB TMEM241 TRMT10A 
TNFSF13B 
MED11 COTL1 ETNK1 AL353791.1 
CNOT2 
CYGB CYP26B1 TTI1 MAPK6 
POMGNT1 
FYB LRRC59 TMEM41B ASNA1 
SUB1 
ADH7 PCDHB11 AC012123.1 PLK2 
GDA 
ZNF449 SLC9A3R2 TBCA CTSO 
ZNF148 
CDIPT PKNOX2 RAB38 MYLIP 
KCNT2 
BTLA CBFA2T3 LILRB1 C11orf71 
MGP 
VMA21 CREB1 SSPN SAMD9 
NECAP2 
SLC39A10 ELK1 ARMC2 TYSND1 
ANO4 
PPBP CALR ATF4 MLTK 
MFHAS1 
IMPG1 HEYL MAEA IMPACT 
GIGYF2 
MTRNR2L3 SLC7A8 RBMS1 KCNE1L 
ATL1 
TCEB1 KDM2A URM1 CAT 
SLIT2 
KMO SREBF2 UBE2E3 FGF10 
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AMMECR1L 
CACNB2 TMEM194A CD69  
CCDC67 
MTUS1 STK38L C3orf58 ZMAT2 
TUBG1 
LIX1L DYNC1I1 AC011755.1 KCNJ6 
TAPT1 
NCOA1 SGIP1 TECRL OTOR 
ARPP19 
PSME3 E2F5 ZNF667 PPP2R5E 
CXADR 
LARP1 NOVA1 ARPP19 NRXN2 
NIPBL 
IGSF11 BRINP3 B3GALNT1 ZBTB47 
TSPAN6 
CELF3 HMGCR TNFSF13B USF2 
AGO3 
DIRAS1 VPS13D GSDMC CSF2RB 
ZNRF2 
ELN USP6NL ZBED5 UBAP2L 
G2E3 
RSU1 RLIM NPY1R LRRC28 
EIF5 
GAS7 PANK3 RP11-766F14.2 SLC28A1 
RAB18 
FOXP4 HTR7 GJE1 MLLT6 
LMAN1 
HMP19 SDC2 KLRC4 CELSR2 
ZAK 
NLGN2 TEAD1 GABRB1 BCDIN3D 
IPPK 
FAM84B CTCF DDAH1 CELF5 
GSDMC 
SOX13 RBMS1 MMP8 PRND 
ZFHX3 
SMARCC2 USP32 FAM104B ZFP36L1 
HECW1 
GPRC5A SOCS7 OTC ST3GAL2 
REV3L 
HNRNPU SEMA4G TRIM6 CCDC102B 
CDK12 
C6orf141 ETS1 LYRM5 WEE1 
SBNO1 
DYRK1A RAB1A POLR2D SLC8A2 
ACSL3 
NFIX PSD3 TMEM69 C20orf112 
COG5 
HRK BTF3L4 JAGN1 DNAJC14 
EPHA4 
FZD7 SV2A NLRP14 WDFY3 
RNF139 
MAT1A TOX3 FOXO1 SLC8A1 
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RBM39 
IGSF3 RHOT1 MUC4 DESI2 
MFAP3 
CLIP2 PITPNB VAMP2 DCLK3 
ADO 
ZFC3H1 FAM199X PDE4A PEAR1 
ST3GAL6 
KDM5C CLDN12 SPRED3 
ZDHHC21 
LOC101927910 TIMP3 FAM131B 
SPTBN4 FCHO2 SERPINB7 C1orf198 
PTHLH ZMYM4 FOXE1 RARA 
CALD1 YLPM1 HOXC11 PRELP 
NR1D1 KIAA1549L UNC13A EIF4G1 
DAAM2 SUMO2 ASIC1 TACC1 
DAB2IP BTBD10 PXN GLDN 
C9orf57 TMEM168 PCSK2 PBX1 
PLA2G2D MAP9 MYL12A PACSIN1 
SPRED2 ADAMTS6 ALX4 SPIN3 
CNST TCF7L1 UBTF ATXN7L3 
MTSS1L OTUD4 LAMC3 CDK18 
ATCAY RSBN1 TMEM184B ZNF385B 
PVALB EIF4ENIF1 WHSC1 CPLX2 
SPRR1B SEMA3E LCLAT1 DHRS11 
RANBP10 EXOC8 ZFP36 CTNND1 
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Appendix B 
 
Chapter 3 supplementary information.  
Melting curves 
 
Figure 3.8: Melting curve and melting peak of miR1 in MCF 7 cells.  
     
Figure 3.9: Melting curve and melting peak of miR2 in MCF 7 cells.  
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Figure 3.10: Melting curve and melting peak of miR3 in MCF 7 cells.  
 
Figure 3.11: Melting curve and melting peak of miR4 in MCF 7 cells. A sharp 
peak is seen at the Tm of 84 ºC. 
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Figure 3.12: Melting curve and melting peak of miR5 in MCF 7 cells. 
 
Figure 3.13: Melting curve and melting peak of miR1 in LNCaP cells.  
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Figure 3.14: Melting curve and melting peak of miR2 in LNCaP cells.  
 
Figure 3.15: Melting curve and melting peak of miR3 in LNCaP cells.  
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Figure 3.16: Melting curve and melting peak of miR4 in LNCaP cells.  
 
Figure 3.17: Melting curve and melting peak of miR5 in LNCaP cells.  
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Figure 3.18: Melting curve and melting peak of miR2 in BPH1 cells. 
 
Figure 3.19: Melting curve and melting peak of miR3 in BPH1 cells.  
 
 
 
 
152 
 
 
Figure 3.20: Melting curve and melting peak of miR4 in BPH1 cells. 
 
Figure 3.21: Melting curve and melting peak of miR5 in BPH1 cells.  
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Figure 3.22: Melting curve and melting peak of miR1 in PNT1a cells 
 
Figure 3.23: Melting curve and melting peak of miR2 in PNT1a cells.  
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Figure 3.24: Melting curve and melting peak of miR3 in PNT1a cells. 
 
 
Figure 3.25: Melting curve and melting peak of miR4 in PNT1a cells. 
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Figure 3.26: Melting curve and melting peak of miR5 in PNT1a cells. 
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